

CURRICULUM VITAE AND LIST OF PUBLICATIONS

Personal Details

Address and Contact Information at Work:

Department of Health Systems Management
Faculty of Health Sciences
Ben-Gurion University of the Negev
Beer-Sheva 84105, Israel
+972-8-647-7422 (Tel)
+972-8-647-7634 (Fax)
dangr@bgu.ac.il (E-mail)

Address and Contact Information at Home:

20 Gibton Street
Lehavim 8533800, Israel
+972-8-651-2304 (Tel)
+972-52-351-3503 (Mobile)

Education

- B.A. 1991 Open University of Israel, Social Sciences.
- M.Sc. 1996 Ben-Gurion University of the Negev, Department of Industrial Engineering and Management: Health Policy and Management Track (graduated Magna Cum Laude).
Thesis: Cost-Utility Analysis of Implantable Cardioverter Defibrillator Therapy. Advisors: Prof. J. Pliskin & Prof. D. Pilpel.
- Ph.D. 2001 Ben-Gurion University of the Negev, Faculty of Health Sciences, Department of Health Systems Management.
Thesis: Adoption and Diffusion of Technologies in Israeli Medical Centers in an Era of Budget Constraints. Advisors: Prof. J. Pliskin, Dr. D. Vekstein & Dr. Y. Peterburg.

Employment History and Academic Appointments

- 8/2011-7/2015 Chairman, Department of Health Systems Management, Faculty of Health Sciences and Guilford-Glazer Faculty of Business and Management, Ben-Gurion University of the Negev.
- 4/2011-present Associate Professor, Department of Health Systems Management, Faculty of Health Sciences, Ben-Gurion University of the Negev.
- 2008-present Visiting and Adjunct Assistant Professor, Center for the Evaluation of Value & Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine.
- 2008-2009 Sabbatical leave, Center for the Evaluation of Value & Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine.
- 2004-2011 Senior Lecturer, Department of Health Systems Management, Faculty of Health Sciences, Ben-Gurion University of the Negev (Tenure, May 2009).
- 2003-2006 Visiting Scientist, Department of Health Policy and Management, Harvard School of Public Health.
- 2001-2004 Research Fellow, Harvard Clinical Research Institute & Cardiovascular Division, Beth Israel Deaconess Medical Center, Harvard Medical School.
- 2000-2001 Instructor, Department of Health Systems Management, Ben-Gurion University of the Negev.
- 1997-2001 External Lecturer, Ashkelon Regional College under the Academic Auspices of Bar-Ilan University.
- 1996-1999 Teaching Assistant B, Department of Health Systems Management, Ben-Gurion University of the Negev.

Professional Activities

(a) Positions in academic administration

- 1/2016-present Chairman, curriculum committee, Leon and Mathilda Recanati School for Community Health Professions, Faculty of Health Sciences, Ben-Gurion University of the Negev.
- 10/2013-present Member, Ben-Gurion University of the Negev Senate.
- 8/2011-7/2015 Chairman, Department of Health Systems Management, Faculty of Health Sciences and Guilford-Glazer Faculty of Business and Management, Ben-Gurion University of the Negev.
- 8/2011-7/2015 Member- Faculty of Health Sciences curriculum committee, Ben-Gurion University of the Negev.
- 2006-2008 Member- Faculty of Health Sciences graduate students committee, Ben-Gurion University of the Negev.

2005-present	Co-coordinator of the Healthcare Management track, Masters of Public Health Program, Ben-Gurion University of the Negev.
2005-2011	Member - Guilford-Glazer Faculty of Business and Management graduate students committee, Ben-Gurion University of the Negev.
2005-2008	Member - Guilford-Glazer Faculty of Business and Management curriculum committee, Ben-Gurion University of the Negev.
2004-2008	Chair - Curriculum committee - Department of Health Systems Management, Ben-Gurion University of the Negev.
1997-2001	Member of the student admission and curriculum committees, Department of Health Systems Management, Ben-Gurion University of the Negev.

(b) Professional functions outside the university

2016	Organizing Committee- The 9 th Annual Conference of the Israeli Society for Pharmacoeconomics and Outcomes Research (ISPOR-Israel Regional Chapter), Tel-Aviv, July 14 th , 2016.
2016	Member of an advisory committee appointed by the Director General, Ministry of Health to propose a new model for drug pricing in Israel.
2015	Steering Committee- The 2 nd International Conference for Hospital Management (Leadership and Accountability in Managing Hospitals), Tel-Aviv, December 10, 2015.
2015	Organizing Committee- The 8 th Annual Conference of the Israeli Society for Pharmacoeconomics and Outcomes Research (ISPOR-Israel Regional Chapter), Herzliya, April 29-30, 2015.
2014-present	Fellow, the Health Policy Program, Taub Center for Social Policy Studies in Israel, Jerusalem, Israel.
2014-present	Member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Excellence Award Committee. As of 2015, Research Excellence Awards Chair - Application of Pharmacoeconomics and Health Outcomes Research.
2014-2015	Member, committee appointed by the Council for Higher Education and the Ministry of Health to examine the financial arrangements between universities and healthcare institutions providing internship programs for physical therapy students.
2014-2015	Member, committee appointed by the Ministry of Health, The National Council for Obstetrics & Gynecology, Neonatology and Genetics to examine the indications for infertility treatments.
2014	Organizing Committee- The 7 th Annual Conference of the Israeli Society for Pharmacoeconomics and Outcomes Research (ISPOR-Israel Regional Chapter), Herzliya, April 30-May 1, 2014.

- 2013-2014 President of the Israeli Society for Pharmacoeconomics and Outcomes Research (ISPOR-Israel Regional Chapter).
- 2013 Member, committee appointed by the Ministry of Health, The National Council for Prevention, Diagnosis & Treatment of Cancer to examine innovative ways for coverage of new technologies in oncology.
- 2013 Scientific Committee – The 5th International Jerusalem Conference on Health Policy, June 3-5, 2013.
- 2013 Organizing Committee- The 6th Annual Conference of the Israeli Society for Pharmacoeconomics and Outcomes Research (ISPOR-Israel Regional Chapter), Herzliya, April 24-25, 2013.
- 2012 Organizing Committee- The 5th Annual Conference of the Israeli Society for Pharmacoeconomics and Outcomes Research (ISPOR-Israel), Herzliya, May 30-June 1, 2012.
- 2011-2013 Task Force member- Health Economic Evaluation Publication Guidelines. ISPOR- The International Society for Pharmacoeconomics and Outcomes Research.
- 2011 Organizing Committee- The 4th Annual Conference of the Israeli Society for Pharmacoeconomics and Outcomes Research (ISPOR-Israel), Herzliya, March 30-April 1, 2011.
- 2010 Scientific Committee, the Biennial European Conference of the Society for Medical Decision Making, Hall in Tyrol, Austria, May 30-June 2, 2010.
- 2010 Organizing Committee- The 3rd Annual Conference of the Israeli Society for Pharmacoeconomics and Outcomes Research (ISPOR-Israel), Herzliya, March 10-12, 2010.
- 2008 Organizing Committee- The 2nd Annual Conference of the Israeli Society for Pharmacoeconomics and Outcomes Research (ISPOR-Israel), Jerusalem, September 18-19, 2008.
- 2008 Co-chair, the Biennial European Conference of the Society for Medical Decision Making, Engelberg, Switzerland, June 1-4, 2008.
- 2007- 2010 Co-founder and President of the Israeli Society for Pharmacoeconomics and Outcomes Research (ISPOR-Israel).
- 2007 Co-chair, Baskets of Health Services sub-committee; The 8th Dead Sea Conference, Israel.
- 2007 Organizing Committee- The 1st Annual Conference of the Israeli Society for Pharmacoeconomics and Outcomes Research (ISPOR-Israel), Caesarea, November 29-30, 2007.

(c) Significant professional consulting

- 2005- present Consulting to various pharmaceutical companies in Israel in areas of health economics and cost-effectiveness analysis.

(d) Editor or member of editorial board of scientific or professional journals

2013-present: Co-Editor in Chief, Value in Health Regional Issues

2013-present: Editor of an annual special issue dedicated to the update of the National List of Health Services in Israel (Medic)

2012-present: Editorial Board, Applied Health Economics and Health Policy

2012-Co-Editor, Value in Health Regional Issues

2011-present: Co-Editor, Value in Health

(e) Ad-hoc reviews for scientific journals

BMJ-Open (2016)

Pharmacoeconomics (2011, 2012, 2013, 2014, 2015)

Value in Health (2008, 2009, 2010, 2011, 2012, 2013, 2014)

Applied Health Economics and Health Policy (2012, 2013, 2014, 2015, 2016)

Expert Review of Pharmacoeconomics & Outcomes Research (2010, 2013, 2014, 2015)

European Journal of Health Economics (2002, 2011, 2012, 2013, 2016)

Health Policy (2002, 2003, 2006, 2008, 2009, 2013, 2015, 2016)

International Journal of Health Policy and Management (2015)

Medical Care (2015)

American Journal of Preventive Medicine (2015)

Diabetes/Metabolism Research and Reviews (2015)

Health Affairs (2014)

The Journal of Market Access and Health Policy (JMAHP) (2014)

Israel Journal of Health Policy Research (2012, 2014, 2016)

BMC- Health Services Research (2007, 2010, 2014)

Cost-Effectiveness and Resource Allocation (2013)

Clinical Therapeutics (2011)

Social Science and Medicine (2011)

BMC Musculoskeletal Disorders (2011)

Cardiology (2010)

Drugs (2010)

Alimentary Pharmacology & Therapeutics (2009)

Journal of General Internal Medicine (2009, 2010)

Heart and Vessels (2009)

Journal of American College of Cardiology (2009)

Health Economics (2008, 2016)
Ha'refuah (Journal of the Israel Medical Association) (2007)
European Journal of Gastroenterology & Hepatology (2006)
Archives of Internal Medicine (2005)
Canadian Medical Association Journal (2004)
International Journal for Quality in Health Care (2004)
British Medical Journal (2003)
Medical Decision-Making (2002, 2003, 2008)

(f) Reviewer for scientific meetings

- 2016 Workshop Review Committee for the ISPOR 19th Annual European Congress, October 29-November 2, 2016, Vienna, Austria.
- 2016 Abstract Review Committee for the ISPOR 21st Annual International Meeting, May 21-25, 2016, Washington, DC.
- 2015 Workshop Review Committee for the ISPOR 18th Annual European Congress, November 7-11, 2015, Milan, Italy.
- 2015 Workshop Review Committee for the ISPOR 20th Annual International Meeting, May 16-20, 2015, Philadelphia, PA.
- 2014 Workshop Review Committee for the ISPOR 19th Annual International Meeting, May 31-June 4, 2014, Montreal, Canada.
- 2013 Abstract reviewer for the 35th Annual Meeting of the Society for Medical Decision Making, October 20-23, 2013, Baltimore, MD.
- 2013 Abstract Review Committee for the ISPOR 18th Annual International Meeting, May 18-22, 2013, New Orleans, LA.
- 2012 Abstract Review Committee for the ISPOR 15th Annual European Congress, November 3-7, 2012, Berlin, Germany.
- 2012 Abstract reviewer for the 34th Annual Meeting of the Society for Medical Decision Making, October 17-20, 2012, Phoenix, Arizona.
- 2012 Abstract Review Committee for the ISPOR 17th Annual International Meeting, June 2-6, Washington DC.
- 2011 Abstract Review Committee for the ISPOR 14th Annual European Congress, November 5-8, 2011, Madrid, Spain.
- 2011 Abstract Review Committee for the ISPOR 16th Annual International Meeting, May 21-26, 2011, Baltimore, MD.
- 2010 Abstract Review Committee for the ISPOR 13th Annual European Congress, November 6-9, 2010, Prague, Czech Republic.
- 2010 Abstract reviewer for the 32nd Annual Meeting of the Society for Medical Decision Making, October 24-27, 2010, Toronto, Ontario, Canada.

- 2009 Abstract Review Committee for the ISPOR 12th Annual European Congress, October 24-27, 2009, Paris, France.
- 2009 Abstract reviewer for the 31st Annual Meeting of the Society for Medical Decision Making, October 18-21, 2009, Hollywood, CA.
- 2009 Abstract Review Committee for the ISPOR 14th Annual International Meeting, May 16-20, 2009, Orlando, FL.
- 2008 Abstract reviewer for the 30th Annual Meeting of the Society for Medical Decision Making, October 18-22, 2008, Philadelphia, PA
- 2008 Abstract Review Committee for the ISPOR 11th Annual European Congress, November 8-11, 2008, Athens, Greece.
- 2008 Abstract Review Committee for the ISPOR 13th Annual International Meeting, May 4-7, 2008, Toronto, Canada.
- 2007 Abstract Reviewer for the 29th Annual Meeting of the Society for Medical Decision Making, October 20-24, 2007, Pittsburgh, PA.
- 2006 Abstract Reviewer for the 28th Annual Meeting of the Society for Medical Decision Making October 14-18, 2006, Cambridge, MA.
- 2006 Abstract Review Committee for the ISPOR 9th Annual European Congress, October 28-31, 2006, Copenhagen, Denmark.
- 2005 Abstract Reviewer for the 27th Annual Meeting of the Society for Medical Decision Making October 21-24, 2005, San Francisco, CA.
- 2005 Abstract Review Committee for the ISPOR 8th Annual European Congress, November 6-8, 2005, Florence, Italy.
- 2005 Abstract Review Committee for the ISPOR 10th Annual International Meeting, May 15-18, 2005, Washington DC.
- 2002 Scientific Review Committee, 24th Annual Meeting of the Society for Medical Decision Making, October 19-23, 2002, Baltimore, MD.

(g) Membership in Professional/Scientific Societies

- 2007-present Israeli Society for Pharmacoeconomics and Outcomes Research (ISPOR-Israel Regional Chapter).
- 2003-present International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
- 2003-2011 Health Technology Assessment International (HTAi)
- 2001-present Society for Medical Decision-Making (SMDM).
- 2000-2004 International Health Economics Association (IHEA).
- 1999-2000 Association for Health Services Research (AHSR).
- 1998-2003 International Society for Technology Assessment in Health Care (ISTAHC) - continued by HTAi
- 1998-2000 American Public Health Association (APHA).

Educational activities

(a) Courses taught

1. Introduction to Epidemiology and Public Health (second year undergraduate students in Health Systems Management), Department of Health Systems Management, Ben-Gurion University of the Negev (teaching fellow; 1995-2000).
2. Health Economics (undergraduate students of Nursing). Ashkelon Regional College under the Academic Auspices of Bar-Ilan University (lecturer; 1996-2001).
3. Health Care Services in Israel (First year undergraduate students in Health Systems Management), Department of Health Systems Management, Ben-Gurion University of the Negev (teaching fellow; 1997-1998).
4. Health Services Research (Third year undergraduate students in Health Systems Management students), Department of Health Systems Management, Ben-Gurion University of the Negev (co-coordinator and instructor; 2000-2001).
5. Third Year Internship Program and Internship Program Seminar (Third year undergraduate students in Health Systems Management students), Department of Health Systems Management, Ben-Gurion University of the Negev (coordinator and instructor; 2000-2001).
6. Introduction to Health Economics (MPH-graduate students). Department of Epidemiology and Health Services Evaluation, Ben-Gurion University of the Negev (lecturer; 2000-2001).
7. Cost-Effectiveness Analysis and Benefit-Cost Analysis in Public Health and Medicine (MPH/MSc graduate students graduate), Harvard School of Public Health (teaching fellow; 2004).
8. Healthcare Systems of the World (MHA\MPH-graduate students), Department of Health Systems Management, Ben-Gurion University of the Negev (lecturer; 2004-present)
9. Healthcare Systems of the World (Third year undergraduate students in Health Systems Management), Department of Health Systems Management, Ben-Gurion University of the Negev (lecturer; 2005-present).
10. Health Technology Assessment (Second and third year undergraduate students in Health Systems Management), Department of Health Systems Management, Ben-Gurion University of the Negev (lecturer; 2005-present).
11. Economic Evaluation of Healthcare Technologies (MHA\MPH-graduate students), Department of Health Systems Management, Ben-Gurion University of the Negev (lecturer; 2005-present).
12. Selected Issues in Health Policy and Management. (MHA graduate students), Department of Health Systems Management, Ben-Gurion University of the Negev. (lecturer; 2012-present).
13. Management of Medical Technologies in Health Care (MHA graduate students), Department of Health Systems Management, Ben-Gurion University of the Negev. (lecturer; 2015-present).

(b) Research Students**Graduated****Masters students**

1. Jonathan Rozenzweig- What are the factors influencing the way in which the doctor makes a use of a new technology in medicine? (MA student- Hebrew University, co-supervised with Ilan Salomon, graduated 2006).
2. Yulia Michaelovitch- Restriction of antibiotic families, impact on phenotype susceptibility pattern of gram-negative bacilli: *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, *Klebsiella*, *Escherichia coli* (MPH student, co-supervised with Drora Fraser and Avraham Borer, graduated 2007).
3. Irit Lior-Zadka- The adherence of patients with latent tuberculosis infection to medical treatment and the factors that influence it (MPH student, co-supervised with Ilana Belmaker, graduated 2007).
4. Irit Gefen- Efficacy and cost of screening tests and treatments for Group B Streptococcal (GBS) infection in neonates whose mothers are GBS carriers (MHA student, co-supervised with Asaf Toker, graduated 2008).
5. Sigal Shafran-Tikva- A model for an early detection of prostate cancer in the gastroenterology unit, Hadassah Ein-Kerem medical center (MHA student, co-supervised with Joseph Lysy, graduated 2009).
6. Ronen Arbel – Diffusion of innovations in health care: does the dual market phenomenon exist? (Masters thesis, graduated 2012).
7. Boris Fishman-Adverse pregnancy outcomes following intrauterine exposure to opioids and specifically to codeine and propoxyphene (MPH student, co-supervised with Amalia Levy, graduated in 2015).
8. Shlomi Codish- Does improved pre-analytic management of glucose samples lead to increased glucose values consistent with pre-diabetes? (MPH student, co-supervised with Lena Novack, graduated 2016).

Doctoral students

1. Noa Triki- The impact of rationalizing drug utilization on health outcomes (Doctoral student, co-supervised with Segev Shani, graduated 2010).
2. Ariel Hammerman- Budget impact analysis of new technologies to be included in the Israeli list of reimbursed health services: an evaluation of a risk sharing approach (Doctoral student, graduated 2012).
3. Ronen Arbel-Modeling the effect of budget-constrained market access to therapy on the health outcomes (Doctoral student, graduated 2014).
4. Gila Shahar- A novel framework for planning and development of physiotherapy human resources in Israel (Doctoral student, co-supervised with Ronit Peled, graduated 2015).

MD students

1. Avi Sabbag- Evaluation of the influence of integrating CT angiography in the workup of acute ischemic stroke on etiological diagnosis and management decision-making. (co-supervised with Itzhak Virguin, Gal Ifergane, Ilan Shelef).
2. Lior Shem-Tov- Suspected left ventricular thrombus- prevalence and clinical characteristics. (co-supervised with Arik Wolak and Noa Liel).

3. Ilia Kumets- Natural history and prognosis of discrete subaortic stenosis. (co-supervised with Arik Wolak and Noa Liel).
4. Ron Gal- Rate and characteristics of patients with normal coronary arteries or non-significant coronary artery disease among patients that underwent elective invasive coronary angiography in Soroka Medical Center angiography lab in 1999-2009. (co-supervised with Arik Wolak).

Current Doctoral students

1. Iftach Sagy- Economic aspects of mass media, and healthcare services utilization in Israel. (co-supervised with Victor Novack).
2. Oded Hammerman-Cost-Effectiveness Analysis of a Multi-Disciplinary Clinic Intervention for frequent attendees suffering from unexplained medical symptoms (co-supervised with Talma Kushnir).
3. Ruth Waitzberg - Physician's perspectives about hospitals' reactions to the adoption of activity-based payments and its outcomes.
4. Noa Gordon (Final topic to be determined).
5. Tal Morgenstin (Final topic to be determined).
6. Sefi Mendelovitch (Final topic to be determined. Currently on leave).

Current Masters students

1. Michal Axelrod- The significance of early new onset of atrial fibrillation complicating acute myocardial infarction. (MPH student, co-supervised with Lena Novack and Harel Gilutz).
2. Arkadi Beitelman- Over use of CT examinations in minor traumatic head injury. (MHA student, co-supervised with Eyal Zimlichman).
3. Adi Levy- Cost-effectiveness of imaging tests in preparation for cataract surgery with different Intra Ocular Lens (IOL) Implantation.
4. Rinat Ribalov- The availability and significance of economic evaluation data for decisions to add new technologies to the benefits package in Israel
5. Ohad Freidman- Construction of a mortality prediction score in hemodialysis patients (co-supervised with Yoseph Haviv and Idan Menashe).
6. Alexandra Braginsky- Is there a difference in attendance of Negev Bedouins to the Emergency Department of the Soroka University Medical Center during Ramadan compared with other periods? (co-supervised with Noga Givon-Lavi and Igal Plakht).
7. Lital Wiersch- An economic evaluation of public financing of in vitro fertilization (IVF) in Israel

Current MD students

1. Adi Katz-Avitan-Work disability in a real world IBD cohort; Crohn's disease versus Ulcerative colitis (co-supervised with Doron Schwartz).

Awards, Citations, Honours, Competitive Fellowships**(a) Honors, Citation Awards**

- 2001 Faculty of Health Sciences Dean's award for outstanding doctoral student (Ben-Gurion University of the Negev, Beer-Sheva, Israel).
- 2003 The Society for Cardiac Angiography & Interventions Drug Eluting Stent Task Force- Working Committee on Cost-Effectiveness/Economics.
- 2004 American Heart Association- Travel Award for the 5th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, Washington DC, May 16-17, 2004.
- 2013 Outstanding poster presentation award. The 5th International Jerusalem Conference on Health Policy, June 3-5, 2013.

(b) Fellowships

- 2001-2002 Fulbright post-doctoral fellowship award.
- 2001-2004 Post-doctoral research fellowship. Cardiovascular Division, Department of Medicine, Beth Israel-Deaconess Medical Center, Harvard Medical School & Harvard Clinical Research Institute.

Scientific Publications

(c) Refereed chapters in collective volumes, Conference proceedings

1. Reuveni H^{PI}, Shvarts S^{PI}, Meyer J^C, **Greenberg C** The media as an avenue of competition between sick funds in Israel under the influence of the National Health Insurance Law. In: Chinitz DP (ed) The Changing Face of Health Systems. Jerusalem, Gefen, 2002.
2. **Greenberg D^{PI}**, Pliskin JS^{PI}. 30 Years of Education and Research in Health Policy and Management. In: Benor DE (ed). Sustaining Change in Medical Education-The Model of the Faculty of Health Sciences, Ben-Gurion University, Israel. Beer-Sheva, Ben-Gurion University of the Negev Press, 2005.
3. **Greenberg D^{PD}**, Cohen DJ^{PI}. Economic considerations of drug-eluting stents. In: Colombo A, Stankovic G (ed). Colombo's Tips & Tricks with Drug Eluting Stents. Abington UK, Taylor and Francis, 2005.
4. **Greenberg D^{PI}**, Neumann PJ^{PI}. League tables for incremental cost-effectiveness ratios. In Kattan MW (ed). Encyclopedia of Medical Decision Making. Thousand Oaks, CA: Sage Publications 2009.
5. Porat N^S, **Greenberg D^{PI}**. Using Nursing Quality Indicators as a Management tool for Quality Improvement. In: Toren O, Picker O (ed). Nursing Leadership and Management in Israeli Hospitals, Jerusalem, Magness Press 2009.
6. **Greenberg D^{PI}**, Hammerman A^S, Pliskin JS^{PI}. The use of economic evaluations for supporting decision making in the process of updating the National List of Health Services in Israel. In. Bin Nun G, Magnezi R (ed). Economic and Social Aspects of Israel's Healthcare System, Zisman Shiber, 2010.
7. **Greenberg D^{PI}**, Neumann PJ^{PI}. Is it cost-effective? It depends on who you ask. In Rosen B, Israeli A, Shortell S (ed). Improving Health and Healthcare. Who is Responsible? Who is Accountable? The Israel National Institute for Health Policy Research, 2011.
- *8. Daichman S^S, **Greenberg D^C**, Pikovsky O^C, Pliskin J^{PI}. How to make a right decision in health care: multi criteria decision analysis in the healthcare system. 2013 International Conference on Digital Technologies (2013), 75-80. (Citations=NA; Impact factor=NA; Journal ranking=NA).

(d) Refereed articles and refereed letters in scientific journals

Citations=1346; h-index=17 (ISI Web of Knowledge) (May 1, 2016)

Citations=2257; h-index=24 (Google Scholar) (May 1, 2016)

Citations=1646; h-index=21 (Scopus) (May 1, 2016)

Refereed articles

1. Reuveni H^{PI}, Shvarts S^{PI}, Meyer J^C, Elhayany A^C, **Greenberg D^C**. Newspaper advertising by Health Maintenance Organizations during the reform of healthcare services in Israel. *Isr Med Assoc J* 2001; 3: 422-26. (Citations=2; Impact factor=1.013; Journal ranking=92/153 (Q3) in Medicine, General & Internal).
2. **Greenberg D^S**, Peiser JG^C, Peterburg Y^{PI}, Pliskin JS^{PI}. Reimbursement policies, incentives and disincentives to perform laparoscopic surgery in Israel. *Health Policy* 2001; 56: 49-63. (Citations=8; Impact factor=1.907; Journal ranking=24/71 (Q2) in Health Policy & Services; 37/89 (Q2) in Health Care Sciences & Services).
3. **Greenberg D^{PI}**, Peiser JG^{PI}. Costs and benefits of laparoscopic inguinal hernia repair- is there an economic justification? *Harefuah* 2001; 140: 580-85. (Citations=NA; Impact factor=NA; Journal ranking=NA).
4. Peiser JG^{PI}, **Greenberg D^{PI}**. Laparoscopic versus open appendectomy – results of a retrospective comparison in an Israeli hospital. *Isr Med Assoc J* 2002; 4: 91-4. (Citations=15; Impact factor=1.013; Journal ranking=92/153 (Q3) in Medicine, General & Internal).
5. **Greenberg D^C**, Katz A^{PI}, Epstein M^C, Golovchiner G^C, Ilia R^C, Caspi A^C. Implantable cardioverter defibrillator in Israel: utilization and implantation trends. *Int J Cardiol* 2002; 82:17-23. (Citations=5; Impact factor=4.036; Journal ranking=29/123 (Q1) in Cardiac & Cardiovascular Systems).
6. **Greenberg D^{PD}**, Cohen DJ^{PI}. Examining the economic impact of restenosis: implications for the cost-effectiveness of an antiproliferative stent. *Z Kardiol* 2002; 91(Suppl 3):137-143. (Citations=NA; Impact factor=NA; Journal ranking=NA).
7. **Greenberg D^{PI}**, Pliskin JS^{PI}. Preference based outcome measures in cost-utility analyses: A 20 years overview. *Int J Technol Assess Health Care* 2002; 18: 461-66. (Citations=6; Impact factor=1.308; 65/89 (Q3) in Health Care Sciences & Services).
8. **Greenberg D^S**, Pliskin JS^{PI}, Peterburg Y^{PI}. Decision-making in acquiring medical technologies in Israeli medical centers: a preliminary study. *Int J Technol Assess Health Care* 2003; 19:194-201. (Citations=6; Impact factor=1.308; 65/89 (Q3) in Health Care Sciences & Services).
9. **Greenberg D^{PD}**, Bakhai A^{PD}, Cohen DJ^{PI}. Do the benefits of new technology outweigh the costs? The case of drug-eluting stents. *Am J Drug Deliv* 2003; 1: 255-266. (Citations=NA; Impact factor=NA; Journal ranking=NA).
10. **Greenberg D^{PD}**, Bakhai A^{PD}, Cohen DJ^{PI}. Can we afford to eliminate restenosis? Can we afford not to? *J Am Coll Cardiol* 2004; 43: 513-518. (Citations=83; Impact factor=16.503; Journal ranking=1/123 (Q1) in Cardiac & Cardiovascular Systems).
11. **Greenberg D^{PD}**, Rosen AB^C, Olchanski NV^C, Stone PW^C, Nadai J^C, Neumann PJ^{PI}. Delays in publications of cost-utility analyses conducted alongside clinical trials: registry analysis. *BMJ* 2004; 328:1536-7. (Citations=14; Impact factor=17.810; Journal ranking=5/153 (Q1) in Medicine, General & Internal).

12. Hodgson J^{PI}, Bottner RK^{PI}, Klein LW^{PI}, Walpole HT^C, Cohen DJ^C, Cutlip DE^C, Fenninger RB^C, Firth BG^C, **Greenberg D^C**, Kalisky I^C, Meskan T^C, Powell W^C, Stone GW^C, Zito JP^C, Clark, M^C. Drug-eluting stent task force: final report and recommendations of the working committees on cost-effectiveness/economics, access to care, and medicolegal issues. *Catheter Cardiovasc Interv* 2004; 62:1-17. (Citations=30; Impact factor=2.107; Journal ranking=61/123 (Q2) in Cardiac & Cardiovascular Systems).
13. **Greenberg D^{PD}**, Bakhai A^{PD}, Neumann PJ^C, Cohen, DJ^{PI}. Willingness to pay for avoiding coronary restenosis and repeat revascularization: results from a contingent valuation study. *Health Policy* 2004; 70: 207-216. (Citations=16; Impact factor=1.907; Journal ranking=24/71 (Q2) in Health Policy & Services; 37/89 (Q2) in Health Care Sciences & Services).
14. **Greenberg D^{PD}**, Rosenfield K^C, Garcia LA^C, Berezin RH^C, Lavelle T^C, Fogleman S^C, Cohen DJ^{PI}. In hospital costs of self-expanding nitinol stent implantation vs. balloon angioplasty in the femoropopliteal artery (the VascoCoil trial). *J Vasc Interv Radiol* 2004;15:1065-1069. (Citations=17; Impact factor=2.409; Journal ranking=43/125 (Q2) in Radiology).
15. Neumann PJ^{PI}, **Greenberg D^C**, Olchanski N^C, Stone PW^C, Rosen AB^C. Growth and quality of the cost-utility literature, 1976-2001. *Value in Health* 2005; 8:3-9. (Citations=88; Impact factor=3.279; Journal ranking=14/333 (Q1) in Economics; 7/71 (Q1) in Health Policy & Services; 13/89 (Q1) in Health Care Sciences & Services).
16. **Greenberg D^S**, Peterburg Y^{PI}, Vekstein D^{PI}, Pliskin JS^{PI}. Decision-making to adopt new technologies at the hospital level: insights from Israeli medical centers. *Int J Technol Assess Health Care* 2005; 21(2): 219-227. (Citations=17; Impact factor=1.308; 65/89 (Q3) in Health Care Sciences & Services).
17. Sonnad SS^C, **Greenberg D^C**, Rosen AB^C, Neumann PJ^{PI}. Diffusion of published cost-utility analysis in the field of health policy and practice. *Int J Technol Assess Health Care* 2005; 21:399-402. (Citations=11; Impact factor=1.308; 65/89 (Q3) in Health Care Sciences & Services).
18. Rosen AB^C, **Greenberg D^C**, Stone PW^C, Olchanski NV^C, Neumann PJ^{PI}. Quality of abstracts of papers reporting original cost-effectiveness analyses. *Med Decis Making* 2005; 25:424-428. (Citations=14; Impact factor=3.240; Journal ranking=14/89 (Q1) in Health Care Sciences & Services; 4/24 (Q1) in Medical Informatics).
19. Neumann PJ^{PI}, Rosen AB^C, **Greenberg D^C**, Olchanski NV^C, Pande R^C, Chapman RH^C, Stone PW^C, Ondategui-Parra S^C, Nadai J^C, Siegel JE^C, Weinstein MC^C. Can we better prioritize resources for cost-utility research? *Med Decis Making* 2005; 25:429-436. (Citations=21; Impact factor=3.240; Journal ranking=14/89 (Q1) in Health Care Sciences & Services; 4/24 (Q1) in Medical Informatics).
20. Stone PW^C, Schackman BR^C, Neukermans CP^C, Olchanski NV^C, **Greenberg D^C**, Rosen AB^C, Neumann PJ^{PI}. A synthesis of cost-utility analysis literature in infectious disease. *Lancet Infect Dis* 2005; 5: 383-391. (Citations=14; Impact factor=22.433; Journal ranking=1/78 (Q1) in Infectious Diseases).
21. Neumann PJ^{PI}, Lin PJ^C, **Greenberg D^C**, Berger M^C, Teutsch S^C, Mansley E^C, Weinstein MC^C, Rosen AB^C. Do U.S drug formulary policies reflect evidence of value? *Am J Manag Care*; 2006; 12:30-36. (Citations=16; Impact factor=2.264; Journal ranking=16/71 (Q1) in Health Policy & Services; 41/153 (Q2) in Medicine, General & Internal; 28/89 (Q2) in Health Care Sciences & Services).

22. Bell CM^{PI}, Urbach DR^C, Ray JG^C, Bayoumi A^C, Rosen AB^C, **Greenberg D^C**, Neumann PJ^{PI}. Bias in published cost-effectiveness studies: systematic review. *BMJ* 2006; 332: 699-703. (Citations=166; Impact factor=17.810; Journal ranking=5/153 (Q1) in Medicine, General & Internal).
23. Brauer CA^{PD}, Rosen AB^C, **Greenberg D^C**, Neumann PJ^{PI}. Trends in the use of health utilities in published cost-utility analyses. *Value in Health*; 2006; 9:213-218. (Citations=52; Impact factor=3.279; Journal ranking=14/333 (Q1) in Economics; 7/71 (Q1) in Health Policy & Services; 13/89 (Q1) in Health Care Sciences & Services).
24. Talmor D^{PI}, Shapiro N^C, **Greenberg D^{PI}**, Stone PW^C, Neumann PJ^{PI}. When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literature. *Critical Care Medicine* 2006; 34:2738-47. (Citations=56; Impact Factor=6.312; Journal ranking=4/27 (Q1) in Critical Care).
25. Rabinovich M^S, **Greenberg D^{PI}**, Shemer J^{PI}. Threshold values for cost-effectiveness ratio and public funding of medical technologies. *Harefuah* 2007; 146: 453-458. (Citations=NA; Impact factor=NA; Journal ranking=NA).
26. Talmor D^{PI}, **Greenberg D^{PI}**, Howell MD^C, Libson A^C, Novack V^C, Shapiro N^{PI}. The costs and cost-effectiveness of an integrated sepsis treatment protocol. *Critical Care Medicine* 2008; 36: 1168-74. (Citations=53; Impact Factor=6.312; Journal ranking=4/27 (Q1) in Critical Care).
27. **Greenberg D^{PI}**, Wacht O^C, Pliskin JS^C. Factors associated with the full-length publication of studies presented in abstract form at the Annual Meeting of the Society for Medical Decision Making. *Med Decis Making* 2008; 28: 938-942. (Citations=16; Impact factor=3.240; Journal ranking=14/89 (Q1) in Health Care Sciences & Services; 4/24 (Q1) in Medical Informatics).
28. Otero HJ^{PI}, Rybicki FJ^C, **Greenberg D^C**, Neumann PJ^{PI}. Twenty years of cost-utility analysis in medical imaging: are we improving? *Radiology* 2008; 249: 917-925. (Citations=22; Impact factor=6.867; Journal ranking=2/125 (Q1) in Radiology).
29. Hammerman A^S, **Greenberg D^{PI}**. Estimating the budget impact of new technologies added to the National List of Health Services in Israel: stakeholders' incentives for adopting a financial risk-sharing mechanism. *Health Policy* 2009; 89:78-83. (Citations=6; Impact factor=1.907; Journal ranking=24/71 (Q2) in Health Policy & Services; 37/89 (Q2) in Health Care Sciences & Services).
30. Feldblum I^S, German L^C, Bilenko N^C, Shahar A^C, Enten R^C, **Greenberg D^C**, Harman-Boehm I^C, Castel H^C, Shahar DR^{PI}. Nutritional risk and health care use prior to and following an acute hospitalization among the elderly. *Nutrition* 2009; 25:415-420. (Citations=10; Impact factor=2.926; Journal ranking=27/77 (Q2) in Nutrition & Dietetics).
31. **Greenberg D^{PI}**, Siebzeiner M^C, Pliskin JS^C. The process of updating the National List of Health Services in Israel: is it legitimate? is it fair? *Int J Technol Assess Health Care* 2009; 25: 255-271. (Citations=15; Impact factor=1.308; 65/89 (Q3) in Health Care Sciences & Services).
32. Neumann PJ^{PI}, **Greenberg D^C**. Is the U.S. ready for QALYs? *Health Affairs* 2009; 28:1366-71. (Citations=33; Impact factor=4.966; Journal ranking= 1/70 (Q1) in Health Policy & Services; 2/89 (Q1) in Health Care Sciences & Services).
33. Rosen AB^{PI}, Spaulding A^C, **Greenberg D^C**, Palmer JA^C, Neumann PJ^{PI}. Patient adherence: a blind spot in cost effectiveness analyses? *Am J Manag Care* 2009;15:626-632. (Citations=9; Impact factor=2.264; Journal ranking= 16/71 (Q1) in Health Policy & Services; 41/153 (Q2) in Medicine, General & Internal; 28/89 (Q2) in Health Care Sciences & Services).

34. Nelson AL^S, Cohen JT^C, **Greenberg D^C**, Kent DM^{PI}. Much cheaper, almost as good: decrementally cost-effective innovation in the health care marketplace. *Ann Intern Med* 2009; 151:662-667. (Citations=29; Impact factor=17.810; Journal ranking=4/153 (Q1) in Medicine, General & Internal).
35. Triki N^S, Pliskin JS^{PI}, **Greenberg D^{PI}**. Can linking co-payment on drugs to evidence on treatment value improve health outcomes and contain healthcare costs? *Harefuah* 2010;149: 524-28. (Impact factor=NA; Citations=NA; Journal ranking=NA).
36. **Greenberg D^{PI}**, Rosen AB^C, Wacht O^C, Palmer JA^C, Neumann PJ^C. A bibliometric review of cost-effectiveness analyses in the economic and medical literature: 1976-2006. *Med Decis Making* 2010; 30:320-327. (Citations=14; Impact factor=3.240; Journal ranking=14/89 (Q1) in Health Care Sciences & Services; 4/24 (Q1) in Medical Informatics).
37. Meckley LM^{PD}, **Greenberg D^{PI}**, Cohen JT^C, Neumann PJ^{PI}. The adoption of cost-effectiveness acceptability curves in cost-utility analyses. *Med Decis Making* 2010; 30:314-319. (Citations=5; Impact factor=3.240; Journal ranking=14/89 (Q1) in Health Care Sciences & Services; 4/24 (Q1) in Medical Informatics).
38. Brosh D^{PI}, Aassali A^C, **Greenberg D^C**, Kornowski R^{PI}. A novel noninvasive digital arterial pulse wave analysis during deep instructed breathing as an indicator of significant coronary artery disease. *EuroIntervention*; 2010; 5: 847-52. (Citations=1; Impact factor=3.769; Journal ranking=36/123 (Q1) in Cardiac & Cardiovascular Systems).
39. Neumann PJ^{PI}, Auerbach H^C, Cohen JT^C, **Greenberg D^C**. Low-value services in value-based insurance design. *Am J Manag Care*; 2010;16:280-286. (Citations=17; Impact factor=2.264; 16/71 (Q1) in Health Policy & Services; Journal ranking=41/153 (Q2) in Medicine, General & Internal; 28/89 (Q2) in Health Care Sciences & Services).
40. **Greenberg D^{PI}**, Earle C^C, Fang C^C, Eldar-Lissai A^C, Neumann PJ^{PI}. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. *J Natl Cancer Inst*; 2010; 102: 82-88. (Citations=61; Impact factor=12.583; Journal ranking=8/211(Q1) in Oncology).
41. Otero HJ^{PI}, Rybicki FJ^C, **Greenberg D^C**, Mitsouras D^C, Mendoza JA^C, Neumann PJ^{PI}. Cost-effective diagnostic cardiovascular imaging: when does it provide good value for the money? *Int J Cardiovasc Imaging* 2010; 26: 605-612. (Citations=18; Impact factor=1.810; Journal ranking=58/125 (Q2) in Radiology).
42. Mahoney EM^{PI}, **Greenberg D^{PD}**, Lavelle TA^C, Berezin RH^C, Ishak J^C, Caro JJ^C, Yadav JS^C, Gray W^C, Wholey M^C, Cohen DJ^{PI}. Costs and cost-effectiveness of carotid stenting vs. Endarterectomy for patients at increased surgical risk: results from the SAPPHERE trial. *Catheter Cardiovasc Interven* 2011;77: 463-72. (Citations=21; Impact factor=2.107; Journal ranking=61/123 (Q2) in Cardiac & Cardiovascular Systems).
43. Hammerman A^S, Lipschitz Y^C, Pliskin JS^{PI}, **Greenberg D^{PI}**. Public finance of off-label use of drugs. *Harefuah*; 2011;150:163-167. (Impact factor=NA; Citations=NA; Journal ranking=NA).
44. **Greenberg D^{PI}**, Neumann PJ^{PI}. Does adjusting for health-related quality of life matter in economic evaluations of cancer-related interventions? *Exp Rev Pharmacoeconomics Outcomes Res* 2011; 11; 113-19. (Citations=4; Impact Factor=1.669; 33/71 (Q2) in Health Policy & Services).
- *45. Fang CH^C, Otero HJ^C, **Greenberg G^C**, Neumann PJ^{PI}. Cost-utility analyses of diagnostic laboratory tests: a systematic review. *Value in Health* 2011;14:1010-18. (Citations=7; Impact factor=3.279; Journal ranking=14/333 (Q1) in Economics; 7/71 (Q1) in Health Policy & Services; 13/89 (Q1) in Health Care Sciences & Services).

- *46. Dreier J^S, Almog Y^C, Sprung CL^C, Codish S^C, Klein M^C, Einav S^C, Bar-Lavie Y^C, Singer PP^C, Nimrod A^C, Sachs J^C, Talmor D^C, Friger M^C, **Greenberg D^C**, Olsfanger D, Hersch M^C, Novack V^{PI} for SEPSIS-ISR Group. Intensive care admissions with sepsis: temporal trends in patient characteristics and survival - A multicenter analysis. *Critical Care Medicine* 2012; 40: 855-60. (Citations=10; Impact Factor=6.312; Journal ranking=4/27 (Q1) in Critical Care).
- *47. Hammerman A^S, Feder-Bubis P^C, **Greenberg D^{PI}**. Financial risk-sharing in updating the National List of Health Services in Israel: stakeholders' perceived interests. *Value in Health* 2012; 15: 737-742. (Citations=4; Impact factor=3.279; Journal ranking=14/333 (Q1) in Economics; 7/71 (Q1) in Health Policy & Services; 13/89 (Q1) in Health Care Sciences & Services).
- *48. Hammerman A^S, **Greenberg D^{PI}**. Risk sharing schemes – A new paradigm in adopting innovative pharmaceuticals. *Harefuah* 2012;151: 306-309. (Citations=NA; Impact Factor=NA; Journal ranking=NA).
- *49. Husereau D^C, Drummond M^C, Petrou S^C, Carswell C^C, Moher D^C **Greenberg D^C**, Augustovski F^C, Briggs AH^C, Mauskopf J^C, Loder E^C, on behalf of the CHEERS Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement. *BMJ* 2013; 346:f1049. (*The CHEERS statement is being simultaneously published in BMC Medicine, BMJ, BJOG: An International Journal of Obstetrics and Gynaecology, Clinical Therapeutics, Cost Effectiveness and Resource Allocation, The European Journal of Health Economics, International Journal of Technology Assessment in Health Care, Journal of Medical Economics, Pharmacoeconomics, and Value in Health*). (Citations=59; Impact factor=17.810; Journal ranking=5/153 (Q1) in Medicine, General & Internal; 130 additional citations in other journals. Report published in *BMJ* is a highly cited paper-top 1% in the academic field of Clinical Medicine. Report published in *Pharmacoeconomics* is a highly cited paper-top 1% in the field of Economics and Business).¹
- *50. Husereau D^C, Drummond M^C, Petrou S^C, Carswell C^C, Moher D^C, **Greenberg D^C**, Augustovski F^C, Briggs AH^C, Mauskopf J^C, Loder E^C, on behalf of the CHEERS Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) – Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluations Publication Guidelines Task Force. *Value in Health* 2013; 16:231-250. (Citations=129; Impact factor=3.279; Journal ranking=14/333 (Q1) in Economics; 7/71 (Q1) in Health Policy & Services; 13/89 (Q1) in Health Care Sciences & Services; highly cited paper-top 1% of the academic field of Pharmacology and Toxicology).
- *51. **Greenberg D^{PI}**, Hammerman A^C, Vinker S^C, Shani A^C, Yermiahu Y^C, Neumann PJ^{PI}. Which is more valuable, longer survival or better quality of life? Israeli oncologists' and family physicians' attitudes toward the relative value of new cancer and congestive heart failure interventions. *Value in Health* 2013; 16: 842-47. (Citations=2; Impact factor=3.279; Journal ranking=14/333 (Q1) in Economics; 7/71 (Q1) in Health Policy & Services; 13/89 (Q1) in Health Care Sciences & Services).
- *52. Lin PJ^C, Concannon TW^C, **Greenberg D^C**, Cohen JT^C, Rossi G^C, Hille J^C, Auerbach HR^C, Fang CH^C, Nadler E^C, Neumann PJ^{PI}. Does Framing of Cancer Survival Affect Preferences for Care? A Population-Based Contingent Valuation Study. *Exp Rev Pharmacoeconomics Outcomes Res* 2013; 13: 513-522. (Citations=1; Impact Factor=1.669; 33/71 (Q2) in Health Policy & Services).

¹ H-index calculations exclude the multiple publications of the CHEERS statement

- *53. **Greenberg D^{PI}**, Hammerman A^C, Vinker S^C, Shani A^C, Yermiahu Y^C, Neumann PJ^{PI}. Oncologists' and Family Physicians' Views on Value for Money of Cancer and Congestive Heart Failure Interventions. *Isr J Health Policy Res* 2013; 2 (1): 44. (Citations=3; Impact Factor=1.213; Journal ranking=53/71 (Q3) in Health Policy & Services).
- *54. Finestone AS^{PI}, Volfsons S^C, Milgrom C^C, Lahad A^C, Moshe S^C, Agar G^C, **Greenberg D^C**. The case for Orthopaedic Medicine in Israel. *Isr J Health Policy Res* 2013; 2(1):42. (Citations=1; Impact Factor=1.213; Journal ranking=53/71 (Q3) in Health Policy & Services).
- *55. Daichman S^S, **Greenberg D^C**, Pikovsky O^C, Pliskin J^{PI}. Finding the best way to share budget in health care: a review of current approaches. *Journal of Information, Control and Management Systems* 2013;11:75-85. (Citations=NA; Impact factor=NA; Journal ranking=NA).
- *56. Kushnir T^{PI}, **Greenberg D^C**, Hadari I^C, Yermiahu Y^C, Bachner Y^{PI}. Is burnout associated with referral rates among primary care physicians? *Family Practice* 2014; 31: 44-50. (Citations=4; Impact Factor=1.861; Journal ranking=56/153 (Q2) in Medicine, General & Internal; 6/19 (Q2) in Primary Health Care).
- *57. Gavius A^C, **Greenberg D^{PI}**, Hammerman A^S, Segev E^C (*alphabetical order*). Impact of a Financial Risk-Sharing Scheme on Budget-Impact Estimations: A Game-Theoretic Approach. *Eur J Health Econ* 2014;15: 553-61. (Citations=0; Impact Factor=1.774; Journal ranking=53/333 (Q1) in Economics; 29/71 (Q2) in Health Policy & Services).
- *58. Simon Tuval T^C, Triki N^C, Chodick G^C, **Greenberg D^{PI}**. Determinants of cost-related non-adherence to medications among chronically ill patients in Maccabi Healthcare Services, Israel. *Value in Health Regional Issues* 2014; 4C: 41-46. (Citations=NA; Impact factor=NA; Journal ranking=NA).
- *59. Odes S^{PI}, **Greenberg D^{PI}**. Medico-economic review of early intervention with biological agents in the treatment of inflammatory bowel diseases. *ClinicoEconomics and Outcomes Research* 2014; 6: 431-443. (Citations=NA; Impact factor=NA; Journal ranking=NA).
- *60. Burisch J, Vardi H, Pedersen N, Brinar M, Cukovic-Cavka S, Kaimakliotis I, Duricova D, Bortlik M, Shonová O, Vind I, Avnstrøm S, Thorsgaard N, Krabbe S, Andersen V, Dahlerup JF, Kjeldsen J, Salupere R, Olsen J, Nielsen KR, Manninen P, Collin P, Katsanos KH, Tsianos EV, Ladefoged K, Lakatos L, Bailey Y, O'Morain C, Schwartz D, Lupinacci G, De Padova A, Jonaitis L, Kupcinskis L, Turcan S, Barros L, Magro F, Lazar D, Goldis A, Nikulina I, Belousova E, Fernandez A, Pineda JR, Almer S, Halfvarson J, Tsai HH, Sebastian S, Friger M, **Greenberg D^C**, Lakatos PL, Langholz E, Odes S, Munkholm P; for the EpiCom Group. Costs and Resource Utilization for Diagnosis and Treatment during the Initial Year in a European Inflammatory Bowel Disease Inception Cohort: An ECCO-EpiCom Study. *Inflamm Bowel Dis* 2015; 21:121-31. (Citations=6; Impact Factor=4.464; Journal ranking=15/76 (Q1) in Gastroenterology & Hepatology).
- *61. Simon Tuval T^C, Triki N^C, Chodick G^C, **Greenberg D^{PI}**. The association between adherence to cardiovascular medications and healthcare utilization. *Eur J Health Econ* 2016; 17: 603-10. (Citations=0; Impact Factor=1.774; Journal ranking=53/333 (Q1) in Economics; 29/71 (Q2) in Health Policy & Services).
- *62. **Greenberg D^{PI}**, Schwartz D^C, Vardi H^C, Friger M^C, Sarid O^C, Slonim-Nevo V^C, Odes S^{PI}. Health-related utility weights in a cohort of real-world Crohn's disease patients. *J Crohns Colitis* 2015; 9: 1139-45. (Citations=0; Impact Factor=6.234; Journal ranking=8/76 (Q1) in Gastroenterology & Hepatology).

- *63. Sagy I^S, **Greenberg D^{PI}**, Barski L^C, Novack V^{PI}. Health Scores: A Chronicle Unnecessary Anxiety. *Harefuah* 2016 (Accepted). (Impact factor=NA; Citations=NA; Journal ranking=NA).
- *64. Simon-Tuval T^{PI}, Neumann PJ^{PI}, **Greenberg D^{PI}**. Cost-Effectiveness of Adherence-Enhancing Interventions: A Systematic Review. *Exp Rev Pharmacoeconomics Outcomes Res* 2016; 16:67-84. (Citations=0; Impact Factor=1.669; 33/71 (Q2) in Health Policy & Services).
- *65. Arbel R^S, **Greenberg D^{PI}**. Rethinking cost-effectiveness in the era of zero healthcare spending growth. *Int J Equity Health* 2016; 15: 33. (Citations=0; Impact Factor=1.573; 51/147 (Q2) in Public, Environmental & Occupational Health).
- *66. Slonim-Nevo V^C, Sarid O^C, Friger M^C, Schwartz D^C, Chernin E^S, Sergienko R, Shahar I^S, Vardi H^C, Rosenthal A^C, Mushkalo A^C, Ben-Yakov D^C, Abu Freha N^C, Munteanu D^C, Gaspar N^C, Eidelman L^C, Dizengof V^C, Segal A^C, Fich A^C, **Greenberg D^C**, Odes S^{PI}, on behalf of the Israeli IBD Research Nucleus (IIRN). Effect of psychosocial stressors on patients with Crohn's disease: threatening life experiences and family. *Eur J Gastroen Hepat* 2016; 28: 1073-81 (Citations=0; Impact Factor=2.253; Journal ranking=47/76 (Q3) in Gastroenterology & Hepatology).
- *67. Dankner R^{PI}, Bachner YG^C, Ginsberg G^C, Ziv A^C, Ben David H^S, Litmanovitch-Goldstein D^S, Chodick G^C, Balicer R^C, Tanne D^C, **Greenberg D^{PI}**. Correlates of well-being among caregivers of long-term community-dwelling stroke survivors. *Int J Rehab Research* 2016; 39: 326-330. (Citations=0; Impact Factor=1.284; Journal ranking=31/70 (Q2) in Rehabilitation).
- *68. Arbel R^{PI}, Hammerman A^C, Triki N^C, **Greenberg D^C**. PCSK9 Inhibitors May Improve Cardiovascular Outcomes- Can We Afford Them? *Int J Cardiol* 2016; 220: 242-245. (Citations=0; Impact Factor=4.036; Journal ranking=28/123 (Q1) in Cardiac & Cardiovascular Systems).
- *69. Klang E^{PI}, Beytelman A^S, **Greenberg D^{PI}**, Or J^C, Guranda L^C, Konen E^C, Zimlichman E^{PI}. Overuse of head CT examinations for the investigation of minor head trauma: analysis of contributing factors. *J Am Coll Radiol*. 2016 Nov 8. pii: S1546-1440(16)30808-0. doi: 10.1016/j.jacr.2016.08.032. [Epub ahead of print] (Citations=0; Impact Factor=2.929).
- *70. Slonim-Nevo V, Sarid O, Friger M, Schwartz D, Sergienko R, Pereg A, Vardi H, Singer T, Chernin E, **Greenberg D**, Odes S on behalf of the Israeli IBD Research Nucleus (IIRN). Effect of threatening life experiences and adverse family relations in ulcerative colitis: Analysis using structural equation modeling, and comparison with Crohn's disease. *Eur J Gastroen Hepat* 2016; 28: 1073-81 (Citations=0; Impact Factor=2.253; Journal ranking=47/76 (Q3) in Gastroenterology & Hepatology).

Editorials and commentaries

1. **Greenberg D^{PI}**, Pliskin JS^{PI}. Using health state classification systems for utility elicitation in the elderly. *Med Decis Making* 2006; 26:220-222. (Citations=0; Impact factor=3.240; Journal ranking=14/89 (Q1) in Health Care Sciences & Services; 4/24 (Q1) in Medical Informatics).
2. Bakhai A^{PI}, **Greenberg D^{PI}**. Clinical trials and health economics- a marriage of convenience or a marriage made in heaven? *J Med Econ* 2008; 11: 541-546. (Citations=NA; Impact factor=NA; Journal ranking=NA).

- *3. Boncz I^{PI}, Kaló Z^{PI}, Ibrahim MIM^{PI}, **Greenberg D**^{PI}. Further steps in the development of pharmaco-economics, outcomes research and health technology assessment in Central and Eastern Europe, Western Asia and Africa. *Value in Health Regional Issues* 2013; 2: 169-170. (Citations=NA; Impact factor=NA; Citations=NA; Journal ranking=NA).
- *4. **Greenberg D**^{PI}, Ibrahim MIM^{PI}, Boncz I^{PI}. What are the challenges in conducting cost of illness studies? *Value in Health Regional Issues* 2014; 4C: 115-116. (Impact factor=NA; Citations=NA; Journal ranking=NA).
- *5. **Greenberg D**^{PI}, Boncz I^{PI}, Ibrahim MIM^{PI}. High quality, scientific rigor, and diversity: Value in Health Regional Issues is getting its impact. *Value in Health Regional Issues* 2015; 7C: 104-105. (Impact factor=NA; Citations=NA; Journal ranking=NA).
- *6. **Greenberg D**^{PI}, Neumann PJ^{PI}. Cost-effectiveness analysis expands its reach worldwide. *Value in Health Regional Issues* 2015; 10C: 101-102. (Impact factor=NA; Citations=NA; Journal ranking=NA).

Letters

- *1. Husereau D^C, Drummond M^C, Petrou S^C, **Greenberg D**^C, Mauskopf J^C, Augustovski F^C, Briggs AH^C, Moher D^C, Loder E^C, Carswell C^C. Reply to Roberts et al: CHEERS is Sufficient for Reporting Cost-Benefit Analysis, but May Require Further Elaboration. *Pharmacoeconomics*. 2015; 33: 535-6.

(e) Published scientific reports and technical papers (executive summary)

1. **Greenberg D**. Cost-Effectiveness Analysis of Implantable Cardioverter Defibrillator (ICD) Therapy. The Israel National Institute for Health Policy and Health Services Research, 1996-1997 Annual Research Report. (Available at: <http://www.israelhpr.org.il/e/88/283.htm>). July 1998.
2. Shvarts S, Reuveni H, Meyer J, **Greenberg D**. Advertising in the Denominational and Ethnic Press: Competition Among Israeli Health Funds and The National Health Insurance Law. The Israel National Institute for Health Policy and Health Services Research, 1997-1998 Annual Research Report. (Available at: <http://www.israelhpr.org.il/e/88/305.htm>). May 1999.
3. Elhayany A, Goldfarb D, Vardy D, Sherf M, **Greenberg D**, Harari E, Peterburg Y. Evaluation of Different Models for Providing Specialist Services. The Israel National Institute for Health Policy and Health Services Research, 1998-1999 Annual Research Report. (Available at: <http://www.israelhpr.org.il/e/88/347.htm>). March 2001.
4. Sherf M, Peterburg Y, **Greenberg D**, Sherer N, Zmora I. The Impact of National Insurance Legislation on After-hours Health Services in the Southern District of Kupat Holim Clalit. The Israel National Institute for Health Policy and Health Services Research, 1997-1998 Annual Research Report. (Available at: <http://www.israelhpr.org.il/e/88/303.htm>). June 2001.
5. Shvarts S, Reuveni H, Meyer J, **Greenberg D**. HMO Newspaper Advertising in a New, Competitive Israeli Health Care Market. The Israel National Institute for Health Policy and Health Services Research, 1996-1997 Annual Research Report (Available at: <http://www.israelhpr.org.il/e/88/284.htm>). December 2001.

6. Pliskin J, Peterburg Y, **Greenberg D**. Decision-making in Acquiring Medical Technologies in Israeli Medical Centers: A Preliminary Study. The Israel National Institute for Health Policy and Health Services Research, 1997-1998 Annual Research Report. (Available at: <http://www.israelhpr.org.il/e/88/291.htm>). December 2001.
7. **Greenberg D**, Pliskin J, Peiser J, Peterburg Y. Determinants of the Adoption and Diffusion of Laparoscopic Surgery in the Israeli Health Care System. The Israel National Institute for Health Policy and Health Services Research, 2000-2001 Annual Research Report. (Available at: <http://www.israelhpr.org.il/e/88/378.htm>). December 2001.
8. Peterburg Y, Sherf M, **Greenberg D**. The Impact of the National Health Insurance Law on Health Services Utilization of the Bedouin Population in the Negev. The Israel National Institute for Health Policy and Health Services Research, 1996-1997 Annual Research Report. (Available at: <http://www.israelhpr.org.il/e/88/273.htm>). April 2002.
9. Shahar D, Castel H, Harman I, **Greenberg D**, Fraser D. A Clinical Trial to Determine Outcomes and Cost Effectiveness of Models of Nutritional Intervention in Elderly Patients During and Following Acute Hospitalization. The Israel National Institute for Health Policy and Health Services Research, 2005-2006 Annual Research Report. (Available at: <http://www.israelhpr.org.il/e/88/449.htm>). May 2006.
10. Kushnir T, Bachner Y, **Greenberg D**, Hadari I. The association between primary physicians' burnout and annual cost per patient of prescriptions, referrals and diagnostic tests (Available at: <http://www.israelhpr.org.il/e/88/713.htm>). December 2009.
11. **Greenberg D**, Siebzechner MI. The availability and significance of economic evaluation data for decisions to add new technologies to the benefit package in Israel (Available at: <http://www.israelhpr.org.il/e/88/768.htm>). November 2010.
12. Shahar D, Castel H, Harman I, **Greenberg D**, Fraser D. The Prevalence of Under and Malnutrition of Elderly Patients Admitted to an Acute Care Medical Ward and the Impact on Outcome and Use and Cost of Health Services (Available at: <http://www.israelhpr.org.il/e/88/568.htm>). August 2012.
13. **Greenberg D**, Triki N, Chodick G, Simon-Tuval T. Can linking co-payment for drugs to evidence on treatment value improve health outcomes and contain healthcare costs? (Available at: <http://www.israelhpr.org.il/e/88/946.htm>). December 2013.
14. **Greenberg D**, Shani A, Hammerman A, Neumann PJ. What is the Value of a Quality-Adjusted Life Year (QALY) in Cancer Patients in Israel? (Available at: <http://www.israelhpr.org.il/e/88/944.htm>). February 2014.

(f) Unrefereed or other professional articles and publications

1. Tal O^{PI}, Vaknin S^C, Hakak N^C, Ostfeld I^C, **Greenberg D**^C. Health Technology Assessment International (HTAi) Meeting- Bringing HTA into practice: Rome, June 2005 *Harefuah*; 2006; 145:541-44. (Impact factor=NA; Citations=NA; Journal ranking=NA).
2. **Greenberg D**^{PI}, Pliskin JS^{PI}. Adoption and use of new medical technology at the hospital level. *Hospital* (Official Journal of the European Association of Hospital Managers), 2008 February/March; 18-19. (Impact factor=NA; Citations=NA; Journal ranking=NA).

Lectures and Presentations at Meetings and Invited Seminars

(a) Invited lectures

1. Pliskin J, **Greenberg D**. Cost-effectiveness of laparoscopic procedures. Presented at the World Congress of High-Tech Medicine, Hanover, Germany, October 16, 2000.
2. Chapman RH, **Greenberg D**. Performing cost utility analysis: a web-based registry. Workshop presented at the 19th Annual Meeting of the International Society of Technology Assessment in Health Care, Canmore, Alberta, Canada. June 22, 2003.
3. Siebert U, **Greenberg D**, Kuntz KM, Cohen DJ. Cost-effectiveness of fractional flow reserve testing in drug-eluting stent era: a decision analysis. Presented at the 4th International Munich Symposium on Interventional Cardiology, Munich, October 10-11, 2003.
4. **Greenberg D**. Drug eluting stents: cost-effectiveness. Presented at the Society for Cardiac Angiography & Interventions (SCAI) 27th Annual Scientific Sessions, San-Diego, CA, April 29, 2004 (invited speaker).
5. **Greenberg D**, Neumann PJ. Systematic reviews of cost-effectiveness analyses using electronic and web-based registries. Workshop presented at the International Society of Pharmacoeconomics and Outcomes Research 9th Annual International Meeting, Arlington, VA, USA, May 17, 2004.
6. **Greenberg D**. Potential methodological flaws in drug resource allocation. Presented at a workshop on Patients, Physicians and Pharma-Divergent or congruent approaches to the individual and society. Haifa, April 26-27, 2006 (invited speaker).
7. **Greenberg D**. The use of pharmacoeconomics in the process of updating the National List of Health Services in Israel. Presented at the ISPOR Central and European Forum at the 10th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Dublin, October 20-23 2007 (invited speaker).
8. **Greenberg D**. Is the intervention cost effective? It depends on whom you ask. Presented at the 4th International Jerusalem Conference on Health Policy. Jerusalem, December 7-10, 2009 (invited speaker).
9. **Greenberg D**. The process of updating the National List of Health Services in Israel: Is it legitimate? Is it fair? Presented at ISPOR Poland 2010- the 8th International Conference of the Polish Pharmacoeconomic Society. Warsaw, December 2-3, 2010 (invited speaker).
- *10. **Greenberg D**. Health economics: can we afford personalized medicine? Presented at the Annual Meeting of the Israel Society for Clinical Oncology and Radiotherapy (ISCORT 12), Eilat, January 17, 2013 (invited speaker).

(b) Presentation of papers at conferences/meetings (oral or poster)

1. **Greenberg D**, Katz A, Epstein M, Battler A, Caspi A. ICD implantation in Kupat Holim Clalit-Israel, 1993-1997: have we peaked? Presented at the 45th Annual Meeting of the Israel Heart Society, Jerusalem; April 20-21, 1998.
2. Katz A, **Greenberg D**, Epstein M, Battler A, Caspi A. MADIT and other prophylactic indications for ICD implantation in Kupat Holim Clalit- Israel: 1993-1997. Presented at the 45th Annual Meeting of the Israel Heart Society, Jerusalem; April 20-21, 1998.

3. Shvarts S, Reuveni H, Meyer J, **Greenberg D**. The media as an avenue of competition between sick funds in Israel under the influence of compulsory health insurance law. Presented at the 2nd Jerusalem International Conference on Health Policy, Jerusalem, Israel; December 13-17, 1998.
4. Peiser J, **Greenberg D**. Laparoscopic versus open appendectomy: results of a retrospective comparison at Soroka University Medical Center. Presented at the 20th National Congress of Surgery, Haifa; May 26, 1999.
5. **Greenberg D**, Pliskin J, Peterburg Y. Decision-making in acquiring medical technologies in Israeli medical centers: a preliminary study. Presented at the 1st Annual National Conference for Health Policy, Ramat-Gan; November 24, 1999.
- 5a. **Greenberg D**, Pliskin J, Peterburg Y. Decision-making in acquiring medical technologies in Israeli medical centers: a preliminary Study. Presented at the 16th Annual Meeting of the International Society of Technology Assessment in Health Care, The Hague, The Netherlands; June 18-21, 2000.
6. Sherf M, Peterburg Y, **Greenberg D**, Sherer N, Zmora I. Evaluation of out of hours health services in the Negev region of Clalit Health Services. Presented at the 25th Annual Meeting of Family Practice Society, Eilat; March 2, 2000.
7. **Greenberg D**. The use of quality adjusted life year (QALY) as an outcome measure in cost-effectiveness studies- an overview. Presented at the 16th Annual Meeting of the International Society of Technology Assessment in Health Care, The Hague, The Netherlands, June 18-21, 2000.
8. Peterburg Y, Sherf M, **Greenberg D**. The impact of the National Health Insurance Law on the Bedouin population in the Negev. Presented at the 2nd Annual National Conference for Health Policy, Ramat-Gan: December 13, 2000.
9. **Greenberg D**, Katz A, Epstein M, Golovchiner G, Ilia R, Caspi A. Implantable cardioverter defibrillator in Clalit Health Services- Israel (1993-2000): implantation patterns, utilization and mortality. Presented at the 48th Annual Meeting of the Israel Heart Society, Jerusalem; April 1, 2001.
10. Golovchiner G, **Greenberg D**, Katz A, Epstein M, Ilia R, Caspi A. The impact of the MADIT study publication on the ICD implantation trends in Clalit Health Services-Israel. Presented at the 48th Annual Meeting of the Israel Heart Society, Jerusalem; April 3, 2001.
11. Katz A, **Greenberg D**, Epstein M, Golovchiner G, Ilia R, Caspi A. Seasonal variation in implantable cardioverter defibrillator implantation in Clalit Health Services-Israel. Presented at the 48th Annual Meeting of the Israel Heart Society, Jerusalem; April 3, 2001.
12. **Greenberg D**, Peiser J, Peterburg Y, Pliskin J. Reimbursement policies, incentives and disincentives to perform laparoscopic surgery in Israel. Presented at the 22nd National Congress of Surgery, Tel-Aviv, May 8-9, 2001.
13. **Greenberg D**, Peiser J. Costs and benefits of laparoscopic inguinal hernia repair- is there an economic justification? Presented at the 22nd National Congress of Surgery, Tel-Aviv, May 8-9, 2001.
14. **Greenberg D**, Pliskin JS. The use of preference –based outcome measures in cost-utility analyses- a 20 years overview. Presented at the 17th Annual Meeting of the International Society of Technology Assessment in Health Care, Philadelphia, Pennsylvania, USA, June 3-6, 2001.
15. **Greenberg D**, Katz A, Epstein M, Golovchiner G, Caspi A. Diffusion of implantable cardioverter defibrillator (ICD) in the Israeli health care system- a seven years perspective. Presented at the 17th Annual Meeting of the International Society of Technology Assessment in Health Care, Philadelphia, Pennsylvania, USA, June 3-6, 2001.

16. Epstein M, **Greenberg D**, Katz A, Golovchiner G, Caspi A. The Israeli Clalit Health Services ICD registry over the last 8 years- Presented at the 7th Asian-Pacific Symposium on Cardiac Pacing and Electrophysiology, Beijing, China, October 13-16, 2001.
17. **Greenberg D**, Pliskin JS, Vekstein D, Peterburg Y. Identification and early assessment of emerging technologies in Israel-a feasibility study. Presented at the Annual National Conference for Health Policy- Health and Politics in the 21st Century, Jerusalem, Israel, December 18-19, 2001.
18. Katz A, **Greenberg D**, Epstein M, Golovchiner G, Caspi A. Implantable cardioverter defibrillator in Clalit Health Services-Israel (1993-2000): Implantation patterns and utilization. Presented at the XIVth World Congress of Cardiology, Sydney, Australia, May 5-9, 2002.
19. Katz A, Golovchiner G, **Greenberg D**, Epstein M, Caspi A. The impact of MADIT study publication on the ICD implantation trends in Clalit Health Services-Israel. Presented at the XIVth World Congress of Cardiology, Sydney, Australia, May 5-9, 2002.
20. **Greenberg D**, Pliskin JS, Vekstein D, Peterburg Y. Decision-makers support the establishment of an early warning system in the Israeli health care system. Presented at the 18th Annual Meeting of the International Society of Technology Assessment in Health Care, Berlin, Germany, June 9-12, 2002.
21. **Greenberg D**, Pliskin JS, Peterburg Y. A survey among hospital managers in Israel describes the decision-making process in adopting new technologies. Presented at the 18th Annual Meeting of the International Society of Technology Assessment in Health Care, Berlin, Germany, June 9-12, 2002.
22. **Greenberg D**, Bakhai A, Neumann PJ, Cohen DJ. Avoiding restenosis- a willingness to pay study. Presented at the 24th Annual meeting of the Society for Medical Decision Making, Baltimore, MD, October 20-23, 2002.
23. **Greenberg D**, Bakhai A, Neil N, Berezin RH, Ho KK, Cutlip DE, Kuntz RE, Cohen DJ. Modeling the impact of patient and lesion characteristics on the cost-effectiveness of drug-eluting stents. American College of Cardiology 52nd Annual Scientific Session, Chicago, IL, March 30-April 2, 2003.
24. Olchanski NV, Rosen AB, Chapman RH, **Greenberg D**, Stone PW, Nadai J, Neumann PJ. 25 years of cost-utility analyses: state of the field. Presented at the 26th Annual Meeting of the Society of General Internal Medicine. Vancouver, British Columbia, Apr 30-May 3, 2003.
25. Rosen AB, Olchanski NV, **Greenberg D**, Chapman RH, Neumann PJ. Patient adherence: A blind spot in cost-utility analyses? Presented at the 26th Annual Meeting of the Society of General Internal Medicine, Vancouver, British Columbia, Apr 30-May 3, 2003.
26. Rosen AB, Stone PW, **Greenberg D**, Chapman RH, Olchanski NV, Nadai J, Neumann PJ. Reporting of key data in abstracts of published cost-utility analyses. Presented at the 26th Annual Meeting of the Society of General Internal Medicine, Vancouver, BC, Apr 30-May 3, 2003.
27. Neumann PJ, Olchanski NV, Rosen AB, **Greenberg D**, Chapman R, Stone PW, Nadai J. Are published cost-utility analyses improving? Presented at the 8th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington, VA, May 18-21, 2003.
28. **Greenberg D**, Olchanski NV, Rosen AB, Chapman RH, Nadai J, Stone PW, Neumann PJ. Publication lag in cost-utility analyses conducted alongside clinical trials. Presented at the 19th Annual Meeting of the International Society of Technology Assessment in Health Care, Canmore, Alberta, June 22-25, 2003.

29. Olchanski NV, Rosen AB, **Greenberg D**, Chapman RH, Nadai J, Stone PW, Neumann PJ. The cost-utility analysis registry: a comprehensive public resource. Presented at the 19th Annual Meeting of the International Society of Technology Assessment in Health Care, Canmore, Alberta, Canada. June 22-25, 2003.
30. Siebert U, **Greenberg D**, Kuntz KM, Cohen DJ. Cost-effectiveness of measuring fractional flow reserve to guide coronary interventions in the drug-eluting stent era. Presented at the 25th Annual meeting of the Society for Medical Decision Making, Chicago, IL, October 18-22, 2003.
31. Rosen AB, **Greenberg D**, Olchanski NV, Chapman RH, Neumann PJ. Reporting of key data in abstracts of cost-utility analyses. Presented at the 25th Annual meeting of the Society for Medical Decision Making, Chicago, IL, October 18-22, 2003.
32. Neumann PJ, **Greenberg D**, Rosen AB, Olchanski NV, Chapman R, Weinstein M. 25 years of cost-utility analysis: are we studying what matters? Presented at the 25th Annual meeting of the Society for Medical Decision Making, Chicago, IL, October 18-22, 2003.
33. Siebert U, **Greenberg D**, Kuntz KM, Cohen DJ. Cost-effectiveness of fractional flow reserve testing to guide percutaneous coronary intervention in the drug-eluting stent era: a decision analysis. ISPOR 6th Annual European Congress, Barcelona, Spain, November 9-11, 2003.
34. Siebert U, **Greenberg D**, Kuntz KM, Cohen DJ. Cost-effectiveness of measuring pressure-derived fractional flow reserve to guide coronary interventions in the drug-eluting stent era: insights from a decision-analytic model. American Heart Association. Scientific Sessions 2003, Orlando, FL, November 9-12, 2003.
35. Bakhai A, Dabbous OH, Cohen DJ, Flather MD, **Greenberg D**, Anderson, FA, Gurfinkel EP, White K, Fox KA, for the GRACE Investigators. Variations in Practice Patterns and Costs for Acute Coronary Syndrome Patients by Availability of Percutaneous Coronary Intervention Facilities: Results from the Global Registry of Acute Coronary Events. Presented at the American College of Cardiology 53rd Annual Scientific Session, March 7-10, 2004, in New Orleans, Louisiana, USA.
36. Cohen DJ, Mahoney EM, **Greenberg D**, Natjarian A, Lavelle T, Walsh P, Berezin R, Whitlow P, Yadav J, for the SAPPHERE Investigators. Economic Outcomes of Carotid Stenting vs. Endarterectomy for High Risk Patients: Results from the SAPPHERE Trial. Presented at the American College of Cardiology 53rd Annual Scientific Session, March 7-10, 2004, in New Orleans, Louisiana, USA.
37. **Greenberg D**, White-Davis P, Bakhai A, Cohen DJ. Predictors of perceived risk and concern about repeat revascularization among patients undergoing cardiac catheterization. Presented at the 5th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, Washington DC, May 16-17, 2004.
38. Moy ML, **Greenberg D**, Mahoney EM, Taira DA, Cohen DJ. Beyond chest pain: the independent impact of dyspnea on quality of life among patients undergoing coronary revascularization. Presented at the 5th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, Washington DC, May 16-17, 2004.
39. Cohen DJ, Mahoney EM, **Greenberg D**, Natarajan A, White-Davis P, Lavelle T, Berezin R, Yadav JS. Health-related quality of life following carotid stenting vs. endarterectomy: results from SAPPHERE. Presented at the 5th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, Washington DC, May 16-17, 2004.

40. Neumann PJ, Lin PJ, Rosen AB, **Greenberg D**, Olchanski NV, Weinstein MC. Do drug prices reflect value? do formulary polices? Presented at the 9th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington, VA, May 16-19, 2004.
41. Sonnad SS, **Greenberg D**, Rosen AB, Olchanski N, Chapman R, Neumann PJ. Tracing the diffusion of cost-utility analysis as an innovation. Presented at the 9th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington, VA, May 16-19, 2004.
42. **Greenberg D**, Rosen AB, Stone PW, Olchanski N, Neumann PJ. Diffusion and adoption of cost utility analysis as a methodological innovation. Presented at the 1st meeting of Health Technology Assessment International (HTAi), Krakow, Poland, May 31-June 2, 2004.
43. **Greenberg D**, Rosenfield K, Berezin RH, Lavelle T, Cohen DJ. In hospital costs of self-expanding nitinol stent implantation vs. balloon angioplasty in the superficial femoral and popliteal artery (the VascoCoil trial). Presented at the 1st meeting of Health Technology Assessment International (HTAi), Krakow, Poland, May 31-June 2, 2004
44. Rosen AB, Stone PW, **Greenberg D**, Neumann PJ. Patient adherence: A blind spot in cost-utility analyses? Presented at the 25th Annual meeting of the Society for Medical Decision Making, Atlanta, GA, October 17-20, 2004.
45. **Greenberg D**, Mahoney EM, Caro JJ, Ishak K, Smith GL, Cohen DJ. Cost-effectiveness of carvedilol in patients with left ventricular dysfunction after myocardial infarction- results from the CAPRICORN trial. American College of Cardiology 54th Annual Scientific Session, Orlando, FL, March 2005.
46. **Greenberg D**, Talmor D, Shapiro N, Stone PW, Neumann PJ. Is Critical Care Medicine Cost-Effective? A Systematic Review of the Cost- Effectiveness Literature. Presented at the 2nd meeting of Health Technology Assessment International (HTAi), Rome, Italy, June 20-22, 2005.
47. **Greenberg D**, Winkelmayer WC, Neumann PJ. Prevailing judgments about society's willingness to pay for a QALY or life-year gained. Presented at the 2nd meeting of Health Technology Assessment International (HTAi), Rome, Italy, June 20-22, 2005.
48. Bell CM, Urbach DR, Ray JG, Bayoumi A, Rosen AB, **Greenberg D**, Neumann PJ. Is everything in health care cost-effective? Reported cost-effectiveness ratios in published studies Presented at the 5th International Congress on Peer Review and Biomedical Publication, September 15-17, 2005, Chicago, Illinois.
49. Brosh D, Katz A, Arbel R, Tal Y, **Greenberg D**, Kornowski R. A novel noninvasive digital arterial pulse wave analysis during deep breathing as an indicator of coronary artery disease. Presented at the 53rd Annual Conference of the Israel Heart Society, April 26-27, 2006, Tel-Aviv, Israel.
50. **Greenberg D**, Winkelmayer WC, Rosen AB, Neumann PJ. Prevailing judgment about society's willingness to pay for a QALY: do they vary by country? Have they changed over time? Presented at the 10th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Philadelphia, PA, May 20-24, 2006.
51. Talmor D, **Greenberg D**, Howell M, Donnino M, Lahey D, Wolfe R, Lisbon A, Weiss JW, Shapiro N. Cost-Effectiveness Analysis of an Integrated Sepsis Protocol. Acad. Emerg. Med. 2006 13: S61-b-62S -b
52. Palmer JA, Cohen JT, Cochran GL, Eldar-Lissai A, **Greenberg D**, Lavelle TA, Wang ST, Neumann PJ. Growth, Characteristics, and quality of the cost-utility literature through 2003. Presented at the 9th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Copenhagen, October 28-31, 2006.

53. Chhabra A, Bentley A, Donnell D, **Greenberg D**, Oliver E, Alt V. A health economic evaluation of RHBMP-2 in spine fusion surgery in Germany and UK. Presented at the 9th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Copenhagen, October 28-31, 2006.
54. Chhabra A, Bentley A, Oliver E, Salaun B, **Greenberg D**, Alt V. Comparing the cost-effectiveness of RHBMP-2 treatment of open tibia fractures in Germany, France, and UK. Presented at the 9th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Copenhagen, October 28-31, 2006.
55. Brosh D, Katz A, Arbel R, Tal Y, **Greenberg D**, Kornowski R. A novel noninvasive digital arterial pulse wave analysis during deep breathing as an indicator of coronary artery disease. Presented at the American College of Cardiology 56th Annual Scientific Session, New Orleans, March 24-27, 2007.
56. Chhabra A, Nicklasson L, **Greenberg D**, Alt V. A cost-effectiveness analysis of RHBMP-2 in spine fusion surgery in Sweden and Denmark. Presented at the 12th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington, VA, May 19-23, 2007.
57. Alt V, Chhabra A, Nicklasson L, **Greenberg D**, Schnettler R. Cost-effectiveness analysis of RHBMP-2 in the treatment of open tibia fractures in Sweden and Denmark. Presented at the 12th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington, VA, May 19-23, 2007.
58. Hammerman A, **Greenberg D**. Estimating the budget impact of new technologies added to the national list of health benefits in Israel: stakeholders' incentives for adopting a risk-sharing mechanism. Presented at the 10th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Dublin, October 20-23 2007.
59. Hammerman A, **Greenberg D**. A risk-sharing mechanism for the budget impact estimation of including a new technology in the National List of Health Services: Examining the stakeholders' incentives. Presented at the 6th Annual Health Policy Conference, Tel-Aviv, December 12, 2007.
60. **Greenberg D**, Rosen AB, Palmer JA, Wacht O, Neumann PJ. 30 years of cost-effectiveness analyses: a bibliometric review of articles published in the economic and medical literature: 1976-2005. Presented at the 13th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Toronto, Canada, May 3-7, 2008.
61. **Greenberg D**, Siebzeiner M, Pliskin JS. The process of updating the National List of Health Services in Israel: Is it legitimate? Is it fair? Presented at the 13th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Toronto, Canada, May 3-7, 2008.
62. **Greenberg D**, Cohen JT, Neumann PJ. The adoption and diffusion of cost-effectiveness acceptability curves in published economic evaluations. Presented at the 13th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Toronto, Canada, May 3-7, 2008.
63. **Greenberg D**, Wacht O, Pliskin JS. Factors associated with the full-length publication of studies presented in abstract form at the Annual Meeting of the Society for Medical Decision-Making. Presented at the Bi-Annual European Meeting of the Society for Medical Decision Making (SMDM Europe 2008), Engelberg, Switzerland, June 1-4, 2008.

64. **Greenberg D**, Rabinovich M, Hirsch. Economic evaluation of Fulvestrant (Faslodex) as an additional endocrine step in the treatment sequence for hormone-receptor positive advanced and metastatic breast cancer in Israel. Presented at the 2nd Annual Conference of the Israeli Society for Pharmacoeconomics and Outcomes Research, Jerusalem, September 18-19, 2008.
65. Shafran-Tikva S, Lysy Y, Goldin E, **Greenberg D**. The cost and feasibility of a prostate cancer early detection program in gastroenterology units: the experience of the Hadassah Ein-Kerem Medical Center. Presented at the 2nd Annual Conference of the Israeli Society for Pharmacoeconomics and Outcomes Research, Jerusalem, September 18-19, 2008.
66. **Greenberg D**, Wacht O, Pliskin JS. What is the fate of abstracts presented at the Annual Meeting of the Society for Medical Decision-Making? Presented at the 30th Annual Meeting of the Society for Medical Decision Making, Philadelphia, PA, October 18-22, 2008.
67. Shafran-Tikva S, Lysy Y, Goldin E, **Greenberg D**. A model for an early detection of prostate cancer in the gastroenterology of Hadassah Ein-Kerem Medical Center. Presented at the 12th Meeting of the European Society of Gastroenterology and Endoscopy Nurses and Associates. Vienna, October 18-20, 2008.
68. **Greenberg D**, Earle C, Fang C, Eldar-Lissai A, Neumann PJ. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. Presented at the 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Orlando, FL, May 16-20, 2009.
69. **Greenberg D**, Fang C, Cohen JT, Eldar-Lissai A, Neumann PJ. Growth, characteristics and quality of the cost-utility analysis literature through 2006. Presented at the 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Orlando, FL, May 16-20, 2009.
70. **Greenberg D**, Rabinovich M, Hirsch. Economic evaluation of Fulvestrant (Faslodex) as an additional endocrine step in the treatment sequence for hormone-receptor positive advanced and metastatic breast cancer in Israel. Presented at the 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Orlando, FL, May 16-20, 2009.
71. **Greenberg D**. Economic evaluation of sunitinib, sorafenib, bevacizumab/interferon alpha and temsirolimus in first line treatment of metastatic renal cancer carcinoma in Israel. Presented at the 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Orlando, FL, May 16-20, 2009.
72. Shafran-Tikva S, Lysy J, Goldin E, **Greenberg D**. The feasibility and cost of early detection of prostate cancer in gastroenterology units. Presented at the 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Orlando, FL, May 16-20, 2009.
73. **Greenberg D**, Wacht O, Neumann PJ. Publication of cost-effectiveness analysis and subsequent citations in the medical and health economics literature. Presented at the 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Paris, October 24-27 2009.
74. **Greenberg D**, Cohen JT, Neumann PJ. Are incremental benefits from medical care decreasing? An analysis of QALY gains over time. Presented at the 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Paris, October 24-27 2009.

75. **Greenberg D**, Cohen JT, Fang C, Neumann PJ. How much does adjusting for health-related quality of life matter in cost-effectiveness analysis? A comparison of cost/life year and cost/QALY estimates for cancer interventions. Presented at the 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Paris, October 24-27 2009.
76. **Greenberg D**, Fang C, Cohen JT, Neumann PJ. Preferences for preferences. Presented at the 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Paris, October 24-27 2009.
77. Kushnir T, Bachner Y, **Greenberg D**, Yermiyahu Y, Hadari I. Primary physicians' self assessed communication ability: is it associated with smoking too? Presented at the International Conference on Communication in Healthcare 2009, Miami Beach, Florida, October 4-7, 2009.
78. Kushnir T, Bachner Y, **Greenberg D**, Yermiyahu Y, Hadari I. Primary physicians' burnout and referrals to diagnostic tests and to other providers of health services. Presented at the 4th International Jerusalem Conference on Health Policy. Jerusalem, December 7-10, 2009.
79. Kushnir T, Bachner Y, **Greenberg D**, Yermiyahu Y, Hadari I. Is primary care physicians' burnout associated with prescribing medications and making referrals to diagnostic tests and to other providers of health services? Presented at the 9th Conference of the European Academy of Occupational Health Psychology, Rome, March 29-31, 2010.
80. **Greenberg D**, Cohen JT, Neumann PJ. Are incremental benefits from new technology decreasing? An analysis of QALY gains over time. Presented at the Bi-Annual European Meeting of the Society for Medical Decision Making (SMDM Europe 2010), Hall in Tyrol, Austria, May 30-June 2, 2010.
81. **Greenberg D**, Cohen JT, Fang CH, Neumann PJ. Does adjusting for health-related quality of life matter in cost-effectiveness analyses? A comparison of cost/life-year and cost/QALY estimates. Presented at the Bi-Annual European Meeting of the Society for Medical Decision Making (SMDM Europe 2010), Hall in Tyrol, Austria, May 30-June 2, 2010.
82. **Greenberg D**, Cohen JT, Fang CH, Neumann PJ. Does adjusting for health-related quality of life matter in cost-effectiveness analyses? A comparison of cost/life-year and cost/QALY estimates. Presented at the HTAi 7th Annual Meeting, Dublin, Ireland, June 6-9, 2010.
83. **Greenberg D**, Rosen AB, Neumann PJ. Is it cost-effective? It depends on whom you ask. Presented at the HTAi 7th Annual Meeting, Dublin, Ireland, June 6-9, 2010.
84. Hammerman A, Feder-Bubis P, **Greenberg D**. Adopting a financial risk-sharing scheme for new technologies added to the National List of Health Services in Israel: stakeholders' stated incentives and disincentives. Presented at the 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Prague, November 6-9, 2010.
85. Triki N, Shani S, Rabinovich-Protter D, Mossinson D, Kokia E, **Greenberg D**. The impact of a clinical pharmacist intervention on lipid-lowering in a primary care setting. Presented at the 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Prague, November 6-9, 2010.
86. Hammerman A, Feder-Bubis P, **Greenberg D**. Adopting a financial risk-sharing scheme for new technologies added to the National List of Health Services in Israel: stakeholders' stated incentives and disincentives. Presented at the 8th Annual Conference on Health Policy, Tel-Aviv, December 23, 2010.
87. Triki N, Shani S, Rabinovich-Protter D, Mossinson D, Kokia E, **Greenberg D**. The impact of a clinical pharmacist intervention on lipid-lowering in a primary care setting. Presented at the 8th Annual Conference on Health Policy, Tel-Aviv, December 23, 2010.

88. **Greenberg D**, Wacht O, Siebzeher M. The availability and significance of economic evaluation data for decisions to add new technologies to the benefit package in Israel. Presented at the 8th Annual Conference on Health Policy, Tel-Aviv, December 23, 2010.
89. Triki N, **Greenberg D**, Mossinson D, Shani S. What is the impact of generic substitution on patient outcomes and treatment costs? An HMO experience. Presented at the 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Baltimore, MD, May 21-25, 2011.
90. **Greenberg D**, Wacht O, Siebzeher M. The availability and significance of economic evaluation data for decisions to add new technologies to the benefit package in Israel. Presented at the 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Baltimore, MD, May 21-25, 2011.
91. Shahar G, **Greenberg D**, Peled R. Mapping the professional profile of physical therapists in Israel. Presented at the World Physical Therapy 2011, Amsterdam, June 20-23, 2011.
- *92. Arbel R, Yogev G, **Greenberg D**. Diffusion of innovations in health care; does the dual market phenomenon exist? Presented at the 14th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Madrid, November 5-8, 2011.
- *93. Triki N, Shani S, Mossinson D, **Greenberg D**. The impact of implementing a drug preauthorization policy in a primary care setting. Presented at the 14th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Madrid, November 5-8, 2011.
- *94. Arbel R, **Greenberg D**. Using a population-based, budget-constrained, cost-effectiveness model to assess the health and economic impacts of using statins for primary prevention based on the JUPITER trial intended use population. Presented at the 14th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Madrid, November 5-8, 2011.
- *95. Odes S, Vardi H, **Greenberg D**, Friger M, Stockbrugger R, Moum B, O'Morain C, Langholz E, Munkholm P. Effect of Standard Treatment versus Episodic or Maintenance Infliximab on Healthcare Cost and Quality-Adjusted Life Years in a community-based incidence cohort of adult Crohn's disease patients with 10 years follow-up. Presented at the 7th Congress of ECCO, Barcelona, February 16-18, 2012.
- *96. Shem-Tov L, Wolak A, Liel-Cohen N, **Greenberg D**. Characteristics and outcomes of patients with suspected vs. evident left ventricular thrombus. Presented at the 59th Annual Conference of the Israel Heart Society, Tel-Aviv, April 16-17, 2012.
- *97. Odes S, Vardi H, **Greenberg D**, Friger M, Stockbrugger R, O'Morain, CA, Tsianos EV, Politi P, Clofent J, Moum B, Freitas J, Langholz E, Munkholm PS. Cost-effectiveness of episodic or maintenance infliximab treatment versus standard treatment in a community-based incidence cohort of adult ulcerative colitis patients with 10-years follow-up. Presented at the Digestive Diseases Week, San Diego, CA, USA, May 2012.
- *98. Arbel R, Yogev G, **Greenberg D**. The Dual Market Phenomenon in Diffusion of Health Care Innovations. Presented at the 5th Annual Conference of the Israeli Society for Pharmacoeconomics and Outcomes Research, Herzliya, May 30-June 1, 2012.
- *99. Daichman S, **Greenberg D**, Triki N, Hammerman A, Luxemburg O, Pliskin J. Using the Delphi Method for Selection of Medical Technologies under a Budget Constraint. Presented at the 5th Annual Conference of the Israeli Society for Pharmacoeconomics and Outcomes Research, Herzliya, May 30-June 1, 2012.

- *100. Arbel R, **Greenberg D**. Using a Novel Population-Based, Budget-Constrained Model to Assess the Health Impacts of Using Statins for Primary Prevention Based on the JUPITER Trial Intended Use Population. Presented at the 5th Annual Conference of the Israeli Society for Pharmacoeconomics and Outcomes Research, Herzliya, May 30-June 1, 2012.
- *101. Odes S, **Greenberg D**, Vardi H, Friger M, Stockbrugger R, Munkholm P. Cost-effectiveness of episodic or maintenance infliximab versus standard therapy in an incidence cohort of Crohn's disease patients with 10-years follow-up. Presented at the Summer Meeting of the Israel Gastroenterology Association, Tel-Aviv, September 3rd, 2012.
- *102. Hammerman A, Segev E, Gavious A, **Greenberg D**. Impact of a financial risk-sharing scheme estimations: A game- theoretic approach. Presented at the 15th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Berlin, Germany, November 3-7, 2012.
- *103. Odes S, **Greenberg D**, Vardi H, Friger M, Stockbrugger R, Munkholm P. Cost-effectiveness of episodic or maintenance infliximab versus standard treatment in an incidence cohort of Crohn's disease patients with 10-years follow-up. Presented at the 15th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Berlin, Germany, November 3-7, 2012.
- *104. **Greenberg D**, Neumann PJ, Hammerman A, Shani A, Yirmiahu Y, Vinker S. Longer survival or better quality of life? Israeli family physicians' attitudes toward the relative value of new interventions for cancer and congestive heart failure. Presented at the Annual Scientific Meeting of the Israel Association of Family Physicians, Nazareth, March 20, 2013.
- *105. **Greenberg D**, Neumann PJ, Hammerman A, Shani A, Yirmiahu Y, Vinker S. Is there a "cancer premium"? Israel family physicians' views on cancer and congestive heart failure care. Presented at the Annual Scientific Meeting of the Israel Association of Family Physicians, Nazareth, March 20, 2013.
- *106. **Greenberg D**, Hammerman A, Vinker S, Shani A, Yermiahu Y, Neumann PJ. Which is more valuable, longer survival or better quality of life? Israeli oncologists' and family physicians' attitudes toward the relative value of new cancer and congestive heart failure interventions. Presented at the ISPOR 18th Annual International Meeting, May 18-22, 2013, New Orleans, LA.
- *107. **Greenberg D**, Hammerman A, Vinker S, Shani A, Yermiahu Y, Neumann PJ. Israeli Oncologists' and family physicians' views on access to care, coverage decisions and value for money of cancer and congestive heart failure interventions. Presented at The 5th International Jerusalem Conference on Health Policy, June 3-5, 2013.
- *108. **Greenberg D**, Hammerman A, Shani A, Neumann PJ. Survey results show that Israeli adults are willing to pay higher health taxes for wider coverage of life-saving and life-extending medications. Presented at The 5th International Jerusalem Conference on Health Policy, June 3-5, 2013.
- *109. Daichman S, **Greenberg D**, Triki N, Hammerman A, Luxenburg O, Pliskin J. Using the Delphi method for selecting medical technologies under budget constraints: a feasibility study. Presented at The 5th International Jerusalem Conference on Health Policy, June 3-5, 2013.
- *110. **Greenberg D**, Hammerman A, Vinker S, Shani A, Yermiahu Y, Neumann PJ. Is longer survival more valuable than better quality of life? Israeli physicians' attitudes toward the relative value of innovative interventions in cancer and congestive heart failure. Presented at The 5th International Jerusalem Conference on Health Policy, June 3-5, 2013.

- *111. Simon-Tuval T, Triki N, Chodick G, **Greenberg D**. Determinants of non-adherence to medications among chronic patients in Maccabi Healthcare Services. Presented at The 5th International Jerusalem Conference on Health Policy, June 3-5, 2013.
- *112. Arbel R, **Greenberg D**. Maximizing health outcomes under budget constraints: the case of using statins for primary prevention of adverse cardiovascular events. Presented at The 5th International Jerusalem Conference on Health Policy, June 3-5, 2013.
- *113. Odes S, **Greenberg D**, Vardi H, Friger M, Stockbrugger RW, Longholz E, Munkholm P. The Cost-Effectiveness of Infliximab Is Different in Ulcerative Colitis and Crohn's Disease: Markov Model in a Population-Based Incident Patient Cohort. DDW 2013, May 18-21 2013, Orlando, Florida.
- *114. Lin PJ, Concannon TW, **Greenberg D**, Cohen JT, Rossi G, Hille J, Auerbach HR, Fang CH, Nadler E, Neumann PJ. Does framing of cancer survival affect perceived value of care? Comparing respondents with and without cancer. Presented at the 35th Annual Meeting of the Society for Medical Decision Making, October 19-23, 2013, Baltimore, MD.
- *115. Simon Tuval T, Triki N, Chodick G, **Greenberg D**. Determinants of non-adherence to medications in Maccabi Healthcare Services. Presented at the ISPOR 16th Annual European Congress. November 2-6, 2013, Dublin, Ireland.
- *116. **Greenberg D**, Hammerman A, Shani A, Neumann PJ. Are Israeli adults willing to pay higher health taxes for a wider coverage of life-extending medications? Presented at the ISPOR 16th Annual European Congress. November 2-6, 2013, Dublin, Ireland.
- *117. Daichman S, **Greenberg D**, Triki N, Hammerman A, Luxenburg O, Pliskin J. Using the Delphi method for selecting medical technologies under budget constraints: a feasibility study. Presented at the ISPOR 16th Annual European Congress. November 2-6, 2013, Dublin, Ireland.
- *118. Arbel R, **Greenberg D**. Using lower cost, lower efficacy interventions can improve population health outcomes under budget constraints. Presented at the ISPOR 16th Annual European Congress. November 2-6, 2013, Dublin, Ireland.
- *119. Kafri R, **Greenberg D**, Shames J, Novack L, Melzer I. Cost and cost-effectiveness of treating urgency urinary incontinence - results from a randomized controlled trial. Presented at the ISPOR 16th Annual European Congress. November 2-6, 2013, Dublin, Ireland.
- *120. **Greenberg D**, Ginsberg G, Ziv A, Litmanovitch-Goldstein D, Tanne D, Chodick G, Balicer RD, Dankner R. The relation between the modified Rankin Scale (mRS) scores and utility weights: Results from a survey among community dwelling long-term stroke survivors. Presented at the ISPOR 16th Annual European Congress. November 2-6, 2013, Dublin, Ireland.
- *121. Simon Tuval T, Triki N, Chodick G, **Greenberg D**. The Association between Adherence to Chronic Medications and Healthcare Utilization. Presented at the 7th Annual Conference of the Israeli Society for Pharmacoeconomics and Outcomes Research, Herzliya, April 30 - May 1, 2014.
- *122. Simon Tuval T, Triki N, Chodick G, **Greenberg D**. The Association between Adherence to Chronic Medications and Healthcare Utilization. Presented at the 15th Biennial European Meeting of the Society for Medical Decision Making, Antwerp, Belgium, June 8-10, 2014.
- *123. Sarid O, Slonim-Nevo V, Schwartz D, Dizengof V, Abu Freha N, Eidelman L, Gaspar N, Moshkelo A, Rozental A, Ben Yaakov G, Munteau D, Krugliak P, Fich A, Friger M, Vardi H, **Greenberg D**, Odes S and Israel IBD Nucleus. Recently diagnosed Crohn's disease patients demonstrate mixed coping skills to control their psychological distress. Presented at United European Gastroenterology Week, Vienna, Austria, October 18-22, 2014.

- *124. Friger M, Sarid O, Slonim-Nevo V, Vardi H, **Greenberg D**, Ben Yaakov G, Gaspar N, Dizengof V, Moshkelo A, Munteau D, Rozental A, Abu Freha N, Schwartz D, Krugliak P, Eidelman L, Fich A, Odes S. Association between Crohn's Disease Severity and Specific Socio-Demographic, Quality of Life and Coping Factors. Presented at the ISPOR 17th Annual European Congress. November 8-12, 2014, Amsterdam, the Netherlands.
- *125. Sarid O, Slonim-Nevo V, Vardi H, Schwartz D, Fich A, **Greenberg D**, Friger M, Odes S. Characterization of variables determining satisfaction with life in Crohn's Disease patients. Presented at The 10th Conference of ECCO, February 18-21, 2015, Barcelona, Spain.
- *126. **Greenberg D**, Vardi H, Schwartz D, Friger M, Sarid O, Slonim-Nevo V, Odes S. Predictors of health-related utility weights in a consecutive cohort of real-world Crohn's disease patients in Israel. Presented at the ISPOR 20th Annual International Meeting. Philadelphia, PA, May 16-20, 2015.
- *127. Odes S, Vardi H, Friger M, Schwartz D, Sarid O, Slonim-Nevo V, **Greenberg D**. Healthcare costs of a consecutive cohort of patients with ulcerative colitis and Crohn's disease treated at a tertiary medical center in Israel. Presented at the ISPOR 20th Annual International Meeting. Philadelphia, PA, May 16-20, 2015.
- *128. Arbel R, **Greenberg D**. Rethinking cost-effectiveness in the era of zero healthcare spending growth. Presented at the ISPOR 20th Annual International Meeting. Philadelphia, PA, May 16-20, 2015.
- *129. Simon-Tuval T, Triki N, Chodick G, **Greenberg D**. The association between adherence to cardiovascular medications and health care utilization. Presented at the ISPOR 20th Annual International Meeting. Philadelphia, PA, May 16-20, 2015.
- *130. Friger M, Sarid O, **Greenberg D**, Vardi H, Schwartz D, Slonim-Nevo V, Odes SH. Role of social and psychological factors in determining severity of disease in adult patients with Crohn's disease. Digestive Disease Week (DDW) 2015. Washington DC. May 16-19, 2015.
- *131. Vardi H, Friger M, Sarid O, **Greenberg D**, Schwartz D, Slonim-Nevo V, Odes SH. Characterization of Variables impacting on the Quality of Life of Israeli Patients with Crohn's Disease. Digestive Disease Week (DDW) 2015. Washington DC. May 16-19, 2015.
- *132. Simon-Tuval T, Triki N, Chodick G, **Greenberg D**. The association between adherence to cardiovascular medications and health care utilization. Presented at the 11th Annual National Conference for Health Policy, Tel-Aviv; May 13, 2015.
- *133. Shahar G, **Greenberg D**, Peled, Feder-Bubis P. A framework for human resources planning in healthcare: physical therapy as a case study. Presented at the 11th Annual National Conference for Health Policy, Tel-Aviv; May 13, 2015.
- *134. Arbel R, **Greenberg D**. Modelling the impact of access to treatment alternatives under budget constraints on health outcomes in the intended use population. Presented at the 11th Annual National Conference for Health Policy, Tel-Aviv; May 13, 2015.
- *135. Odes S, Sergienko R, Sarid O, Friger M, Vardi H, Schwartz D, **Greenberg D**, Slonim-Nevo V. Patient-reported Quality of Care in Crohn's Disease and its Social Correlations. The South African Gastroenterological Society SAGES Annual Meeting, Durban, South Africa, August 7-8, 2015.
- *136. Odes S, Sergienko R, Sarid O, Friger M, Schwartz D, Vardi H, **Greenberg D**, Slonim-Nevo V. Subjective pain in Crohn's disease patients affects their psychological functioning and coping strategies: a survey of a community-based cohort. UEG Week 2015, October 24-28, 2015, Barcelona, Spain.

- *137. Schwartz D, Chernin E, Friger M, Sarid O, Vardi H, **Greenberg D**, Slonim-Nevo V, Odes S. Surgery in adult Crohn's disease patients has limited impact on the medical and social burden of disease. UEG Week 2015, October 24-28, 2015, Barcelona, Spain.
- *138. Beytelman E, Klang E, Konen E, **Greenberg D**, Zimlichman E. Excess use of minor head injury CT examinations in the emergency department (ER). Presented at the ECR-European Congress of Radiology 2016, March 3-6, Vienna, Austria.
- *139. Schwartz D, **Greenberg D**, Chernin E, Vardi H, Friger M, Sarid O, Slonim-Nevo V, Odes S. Absenteeism and Presenteeism among Crohn's Disease Patients: Results from a Real-World Cohort in Israel. Presented at the 11th Congress of ECCO-Inflammatory Bowel Diseases, March 16-19, 2016, Amsterdam, The Netherlands.
- *140. Schwartz D, Chernin E, **Greenberg D**, Sarid O, Slonim-Nevo V, Friger M, Vardi H, Odes S. Extraintestinal manifestations of Crohn's disease have a major influence on anxiety levels and coping skills. Presented at the 11th Congress of ECCO-Inflammatory Bowel Diseases, March 16-19, 2016, Amsterdam, The Netherlands.
- *141. Schwartz D, **Greenberg D**, Chernin E, Sarid O, Slonim-Nevo V, Friger M, Vardi H, Odes S. Impact of medication type on patients' health-related quality of life in Crohn's disease. Presented at the 11th Congress of ECCO-Inflammatory Bowel Diseases, March 16-19, 2016, Amsterdam, The Netherlands.
- *142. Gordon N, Stemmer SM, **Greenberg D**, Goldstein DA. Price trajectory of individual cancer drugs following launch. Presented at ASCO Annual Meeting. June 3-7, 2016, Chicago, Illinois.
- *143. Arbel R, Hammerman A, Triki N, **Greenberg D**. PCSK9 inhibitors may improve cardiovascular outcomes-can we afford them? Presented at ISPOR 7th Asia-Pacific Conference, September 3-6, 2016, Singapore.
- *144. Ribalov R, Morgenstin T, **Greenberg D**. Are we indeed fast adopters as we claim to be? An analysis of the time interval from regulatory approval to coverage and reimbursement in the National List of Health Services in Israel. Presented at the ISPOR 19th Annual European Congress. October 29-November 2, 2016, Vienna, Austria.
- *145. Arbel R, Hammerman A, Triki N, **Greenberg D**. Prompt value assessment of breakthrough interventions with limited outcome data. Presented at the ISPOR 19th Annual European Congress. October 29-November 2, 2016, Vienna, Austria.
- *146. Triki N, Ash N, Porath A, Birnbaum Y, **Greenberg D**, Hammerman A. The evolution of risk-sharing agreements in the process of updating the National List of Health Services in Israel. Presented at the ISPOR 19th Annual European Congress. October 29-November 2, 2016, Vienna, Austria.
- *147. Odes S, Vardi H, **Greenberg D**, Schwartz D, Friger M, Chernin E, Sarid O, Slonim-Nevo V. Healthcare costs of inflammatory bowel disease in the biologic era: a study of 2,451 patients with twelve years follow-up evaluation. Presented at the ISPOR 19th Annual European Congress. October 29-November 2, 2016, Vienna, Austria.
- *148. Katz Avitan A, Schwartz D, **Greenberg D**, Friger M, Vardy H, Sarid O, Slonim-Nevo V, Odes S. The impact of inflammatory bowel disease on work productivity: comparison of a real-world sample of patients with Crohn's disease and ulcerative colitis. Presented at the ISPOR 19th Annual European Congress. October 29-November 2, 2016, Vienna, Austria.
- *149. Gordon N, Stemmer SM, **Greenberg D**, Goldstein DA. Market regulation may influence drug price trajectories- a comparison of anti-tumor necrosis factor drug prices in Israel and the USA. Presented at the ISPOR 19th Annual European Congress. October 29-November 2, 2016, Vienna, Austria.

- *150. Gordon N, Stemmer SM, **Greenberg D**, Goldstein DA. The influence of price regulation method on price trajectory-assessment of cancer drug prices in USA, the UK and Israel. Presented at the ISPOR 19th Annual European Congress. October 29-November 2, 2016, Vienna, Austria.

(d) Seminar presentations at universities and institutions

1. **Greenberg D**. Implantable cardioverter defibrillators in Israel: implantation trends, utilization and economic components. Presented at the Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry, May 19, 2000.
2. **Greenberg D**. Avoiding restenosis- a contingent valuation (willingness to pay) study. Presented at the Dana Farber Cancer Institute/Outcomes Research Seminar, Boston, April 11, 2002.
3. **Greenberg D**. Current Issues in health insurance, public health and health policy in Israel. University of Pécs, Hungary. June 29-30, 2015 (summer course).

* Denotes presentations since last appointment

Research Grants

- | | |
|------|---|
| 1996 | The Israel National Institute for Health Policy and Health Services Research. Peterburg Y (PI), Sherf M (PI), Greenberg D (CI). The Impact of the National Health Insurance Law on health services utilization of the Bedouin population in the Negev. \$15,000 (total budget). |
| 1996 | The Israel National Institute for Health Policy and Health Services Research. Greenberg D (PI) Cost -effectiveness and cost-utility analyses of Implantable Cardioverter Defibrillator (ICD) versus drug therapy for patients with malignant ventricular arrhythmias. \$3,000 (total budget). |
| 1997 | The Israel National Institute for Health Policy and Health Services Research. Sherf M (PI), Peterburg Y (PI), Greenberg D (CI), Sherer N (CI). The impact of health insurance legislation on after hours health services in the Negev region. \$17,000 (total budget). |
| 1997 | The Israel National Institute for Health Policy and Health Services Research. Shvarts S (PI), Reuveni H (PI), Meyer J (CI), Greenberg D (CI). Competition in advertisement between health care structures in Israel following the enactment of the Health Insurance Bill. \$71,000 (total budget). |
| 1998 | The Israel National Institute for Health Policy and Health Services Research. Pliskin J (PI), Peterburg Y (PI), Greenberg D (CI). Acquiring advanced medical technologies in Israel: decision-making strategies at medical centers. \$16,000 (total budget). |
| 1998 | The Israel National Institute for Health Policy and Health Services Research. Elhayany A (PI), Peterburg Y (PI), Sherf M (CI), Greenberg D (CI), Vardy D (CI). An assessment of alternative models of specialty medicine in the Israeli health care system. \$67,000 (total budget). |

- 1999 The Israel National Institute for Health Policy and Health Services Research. Pliskin J (PI), Vekstein D (CI), **Greenberg D** (CI). Early identification and assessment of emerging health care technologies in Israel: a feasibility study. \$15,000 (total budget).
- 2000-2001 Israel National Institute for Health Policy and Health Services Research. Pliskin J (PI), Peterburg Y (PI), Peiser J (CI), **Greenberg D** (CI). The determinants of adoption and diffusion of laparoscopic procedures in the Israeli health care system. \$20,000 (total budget).
- 2002-2003 The Israel National Institute for Health Policy and Health Services Research. Pliskin J (PI), Vekstein D (CI), Peterburg Y (CI), **Greenberg D** (CI). Technology adoption in the Israeli health care system in an era of budget constraints. \$55,000 (total budget).
- 2002-2003 Guidant Inc. **Greenberg D** (PI), Cohen DJ (PI). Avoiding restenosis: a willingness to pay (contingent valuation) study. \$55,000 (total budget).
- 2003-2004 RADI Medical Systems. Cohen DJ (PI), **Greenberg D** (CI). Evaluating the cost-effectiveness of Fractional Flow Reserve-based lesion assessment in patients with single-vessel coronary artery disease. \$35,000 (total budget).
- 2003-2004 GlaxoSmithKline (GSK). Cohen DJ (PI), **Greenberg D** (PI). Evaluating the cost and cost-effectiveness of Carvedilol in patients with left ventricular dysfunction after myocardial infarction. \$110,000 (total budget).
- 2005-2007 **Greenberg D** (PI). A grant awarded by the Israeli Council for Higher Education (Planning and Budgeting Committee) to develop a web-based course on Comparative Healthcare Systems. The grant was awarded on a competitive basis. \$18,000 (total budget).
- 2006-2007 The Israel National Institute for Health Policy and Health Services Research. **Greenberg D** (PI), Pliskin JS (PI), Siebzeher M (CI). Using rapid health technology assessment to support decisions to add new technologies to the benefits package: a feasibility study. \$22,000 (total budget). (The budget was awarded but the study was stopped because the public committee for updating the benefits package was not appointed).
- 2007-2008 The Israel National Institute for Health Policy and Health Services Research. **Greenberg D** (PI), Siebzeher M (PI). The availability and significance of economic evaluation data for decisions to add new technologies to the benefit package in Israel. \$18,000 (total budget).
- 2007-2008 The Israel National Institute for Health Policy and Health Services Research. Kushnir T (PI), Bachner Y (PI), **Greenberg D** (CI), Hadari I (CI). The association between primary care physicians' burnout and annual cost per patient of prescriptions, referrals and diagnostic tests. \$30,000 (total budget).
- 2010-2012 The Israeli Ministry of Health. Novack V (PI), Douvdevani A (CI), Almog Y (CI), Talmor D (CI), **Greenberg D** (CI), Codish S (CI), Drieher J (CI). Epidemiology, outcomes and health expenditures of patients hospitalized with primary sepsis: Israel multicenter registry. \$78,000 (total budget).
- 2011-2012 The Israel National Institute for Health Policy and Health Services Research. **Greenberg D** (PI), Neumann PJ (PI), Hammerman A (CI), Shani A (CI). What is the value of a quality adjusted life year in cancer patients in Israel? \$45,000 (total budget).

- 2011-2012 Maccabi HealthCare Services Research Institute. Kushnir T (PI), Bachner Y (PI), **Greenberg D** (CI), Abend Y (CI), Arbelle J (CI). The association between physician's emotional exhaustion, subjective workload and referrals, and treatment costs. \$30,000 (total budget).
- 2011-2012 The Israel National Institute for Health Policy and Health Services Research. **Greenberg D** (PI), Triki N (CI), Chodick G (CI), Simon-Tuval T (CI). Can linking co-payment for drugs to evidence on treatment value improve health outcomes and contain healthcare costs? \$33,000 (total budget).
- 2011-2012 The Israel National Center for Health Policy and Health Services Research. Dankner R (PI), **Greenberg D** (PI), Balicer R (CI), Ginsberg G (CI), Tanne D (CI). Cost effectiveness analysis of available treatments and their provision for acute stroke patients in Israel. \$43,000 (total budget). Grant awarded, but stepped down from being a PI as I have exceeded the maximum number of studies funded simultaneously.
- *2013-2015 The Leona M and Harry B. Helmsley Charitable Trust. Odes S (PI), Friger M (CI), **Greenberg D** (CI), Slonim-Nevo V (CI), Sarid O (CI). Socio-Economic Impact of Crohn's Disease on the Israeli Population. \$570,000 (total budget).
- *2014-2015 The Israel National Center for Health Policy and Health Services Research. **Greenberg D** (PI), Arbel R (PI). Maximization of population health outcomes under a restricted budget. \$25,000 (total budget).
- *2015-2016 The Israel National Center for Health Policy and Health Services Research. **Greenberg D** (PI), Lunenfeld E (PI), Arbel R (CI). An economic evaluation of public financing of in vitro fertilization (IVF) in Israel. \$25,000 (total budget).
- *2016-2017 The Israel National Center for Health Policy and Health Services Research. Finestone A (PI), **Greenberg D** (PI), Azuri J (CI), Groshar D (CI), Tal O (CI), Kalichman L (CI). The Israel National Center for Health Policy and Health Services Research. To what extent do patients with musculoskeletal complaints undergo multiple imaging, and how much does this imaging benefit them? (Final budget not yet determined).
- *2016-2017 Maccabi Healthcare Services Research Institute. Plakht I (PI), Arbelle J (PI), Gilutz H (CI), **Greenberg D** (CI). Prediction of non-fatal health-related outcomes and direct costs during 1 and 5 years following acute myocardial infarction. \$16,500 (total budget).
- *2016-2017 The Israel National Center for Health Policy and Health Services Research. Israeli A (PI), **Greenberg D** (PI). Teaching medical students in the community. \$41,000 (Part of the total budget allocated to Ben-Gurion University)
- *2016-2017 The Israel National Insurance Institute. Dankner R (PI), **Greenberg D** (CI), Balicer R (CI), Chodick G (CI). The financial and occupational security of stroke survivors and the social and economic burden on stroke survivors in Israel. \$25,000.

* Denotes funding received since last appointment

Present Academic Activities

Manuscript submitted for publication

1. Arbel R^S, **Greenberg D**^{PI}. Using Lower Cost Lower Efficacy Statins Improves Overall Health Outcomes for the Normal Cholesterol High Risk Patient population, Under Budget Constraints (Submitted to the American Journal of Managed Care). Impact Factor=2.264; Journal ranking=16/71 (Q1) in Health Policy & Services.
2. Sarid O^C, Slonim-Nevo V^C, Friger M^C, Sergienko R^C, Schwartz D^C, Shahar I^C, Chernin E^C, Ben-Yakov D^C, Abu Freha N^C, Munteanu D^C, Rosenthal A^C, Mushkalo A^C, Gaspar N^C, Eidelman L^C, Dizengof V^C, Segal A^C, Fich A^C, **Greenberg D**^C, Friger M^C, Vardi H^C, Odes S^{PI}, on behalf of the Israeli IBD Research Nucleus (IIRN). Gender Differences in Predictors of Satisfaction with Life in Adult Patients with Crohn's Disease (Submitted to Gut). Impact Factor=14.2; Journal ranking=2/76 (Q1) in Gastroenterology & Hepatology.
3. **Greenberg D**^{PI}, Ginsberg G^C, Ziv A^C, Litmanovitch-Goldstein D^S, Tanne D^C, Chodick G^C, Horowitz E^C, Dankner R^{PI}. The Relation between the Modified Rankin Scale (mRS) Scores and Utility Weights: Results from a Survey among Community Dwelling Long-Term Stroke Survivors (Submitted to Quality of Life Research). Impact Factor=2.486; Journal ranking=13/71 (Q1) in Health Policy & Services.
4. **Greenberg D**, Vardi H, Schwartz D, Sarid O, Slonim-Nevo V, Friger M, Odes S. Healthcare Costs of Adult Patients with Crohn's Disease and Ulcerative Colitis: Findings from a Longitudinal Follow-up Study of a Non-Selected Cohort.
5. Odes S, Friger M, Sergienko R, Schwartz D, Sarid O, Slonim-Nevo V, Singer T, Chernin E, Vardi H, **Greenberg D**. Simple Pain Measures reveal Psycho-Social Pathology in Patients with Crohn's Disease.
6. Gordon N, Stemmer SM, **Greenberg D**, Goldstein DA. Increases in Cancer drug costs following launch in the United States.

Manuscripts in preparation

1. Arbel R^S, Yogevev G^C, **Greenberg D**^{PI}. Mainstream adoption of medical innovation.
2. Odes S, **Greenberg D**, Vardi H., et al. Is infliximab cost-effective in patients with inflammatory bowel disease? A Markov model in a population-based incidence cohort on standard therapy.
3. Daichman S^S, **Greenberg D**^C, Triki N^C, Hammerman A^C, Luxenburg O^C, Pliskin J^{PI}. Using the Delphi method for selecting medical technologies under budget constraints: a feasibility study.
4. **Greenberg D**^{PI}, Novack L^C, Sagy I^C, Hammerman A^C, Shani A^C, Neumann PJ^{PI}. Are Israeli adults willing to pay higher health taxes for a wider coverage of life-extending medications?
5. **Greenberg D**^{PI}, Cohen JT^C, Neumann PJ^{PI}. Is it cost-effective? It depends on whom you ask.
6. Sagy I^S, **Greenberg D**^{PI}. Willingness to pay for cancer treatment: a systematic review.
7. Kafri R^S, **Greenberg D**^C, Shames J^C, Novack L^C, Melzer I^{PI}. Cost and Cost-Effectiveness of Treating Urgency Urinary Incontinence - Results from a Randomized Controlled Trial.

Synopsis of Research

My research activity is integrating areas of health services research, health technology assessment and policy, medical decision-making, health economics, and outcomes research. Since my research focus involves medical, economic, epidemiological and statistical expertise, most of my studies are results of collaborations with scholars in these fields. The following synopsis of research will describe my research agenda and achievements in the past 15 years and will outlay plans for ongoing and further research.

My doctoral dissertation (Ben-Gurion University of the Negev, 2001) focused on technology assessment, decision-making to acquire new technologies and diffusion of innovations, both at the hospital and the national healthcare system level. Subsequent to the completion of my doctoral training my research and areas of interest have focused on the following topics: economic evaluations of technologies and other interventions in healthcare, efforts to improve the methodology and the reporting of cost-effectiveness analyses, practices in using economic evaluations to inform coverage and reimbursement decisions, and dissemination of cost-effectiveness analyses.

During my post-doctoral fellowship at the Harvard Clinical Research Institute (HCRI) in Boston, I was involved in various economic evaluations of innovative devices in the cardiovascular field. These studies evaluated drug-eluting stents for the treatment of coronary artery disease (refereed articles #6, #9, and #10), the use of stenting for peripheral arterial disease (refereed article #14), carotid stenting versus endarterectomy for patients at increased surgical risk (refereed article #42) and an integrated sepsis treatment protocol. Recently, together with colleagues from the Gertner Institute, the Sheba Medical Center, the Ministry of Health, and Clalit Health Services, we have received a grant to estimate the life-long economic impact and cost-effectiveness of increasing tissue plasminogen activator (tPA) use for treating ischemic stroke patients in Israel (research grants 2011-2012). As part of this study we have examined the burden on caregivers of community-dwelling stroke patients (submitted manuscript #2) and assessed the utility weights of stroke survivors (manuscript in preparation #5). I was also involved in a multicenter prospective study to assess the epidemiology, outcomes and health expenditures of patients hospitalized with primary sepsis in Israel (research grant 2010-2012). The retrospective phase of this study is summarized in a manuscript published in *Critical Care Medicine* (refereed article #46). Additional manuscripts addressing the economic implications of severe sepsis are planned.

Cost-effectiveness analysis provides a standard, well-accepted methodological technique for determining whether a health intervention provides value for money, and is used to inform reimbursement and coverage decisions in many countries. The increasing use of economic evaluations in healthcare reinforces the need for standardization of methods to conduct cost-effectiveness analyses, and disseminating these study results. As part of the efforts to standardize the practice of cost-effectiveness research, I was involved in the past 15 years in a series of studies at the Harvard School of Public Health and subsequently at the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center in

Boston, the current home of the Tufts Cost-Effectiveness Analysis Registry. We have published several analyses scrutinizing cost-effectiveness analyses in various medical fields such as infectious diseases (refereed article #20), critical care medicine (refereed article #26), medical imaging (refereed articles # 28, and #41), and cancer-related interventions (refereed article #40). More recently, we have published a paper addressing the cost-effectiveness of diagnostic laboratory tests (refereed article #45).

Further analyses looked at specific issues relating to the methodology used in cost-effectiveness analyses, such the assessment of utility weights to adjust life years gained for patient preferences/health-related quality of life (refereed article #23), the incorporation of patient adherence rates in the economic analysis (refereed article #33), the use of cost-effectiveness acceptability curves and probabilistic sensitivity analyses to address uncertainties (refereed article #36), and whether adjusting life-years gained to health-related quality of life matters in cost-effectiveness analyses (refereed article #44). More recently, I was involved in an effort to standardize the reporting of cost-effectiveness analysis, as part of an ISPOR Task Force. The guidelines have been published as a statement, published simultaneously in 10 peer-reviewed journals (refereed article #49) as well as the full report (refereed article # 50).

We also studied the quality and dissemination of cost-effectiveness analysis in the scientific literature. Initially we described the growth and the quality of the cost-effectiveness literature (refereed article #15). Further to this study, we considered cost-effectiveness analysis as an innovation, and traced its diffusion in the scientific literature (refereed article #17). We also addressed the time lag between the publication of clinical trial results and the cost-effectiveness analyses conducted alongside the trial (refereed article # 11), the lag between conference presentation and the publication of a full-length paper (refereed article #27), publication bias in cost-effectiveness research (refereed article #22), and a bibliometric analysis of cost-effectiveness analyses presenting a cost per QALY ratio and published in the medical and health economic literature (refereed article #35).

One major area of interest relates to decisions to publicly fund new technologies in healthcare both in Israel and abroad and the use of cost-effectiveness analysis to inform coverage and reimbursement decisions. My early research in the United States examined whether drug formulary policies reflect evidence on drug value (refereed article #21). We also analyzed whether the process of updating the National List of Health Services in Israel follows the accountability for reasonableness framework outlined by Daniels and Sabin (refereed article #31). We also examined the availability and significance of data from economic evaluations in Israel and suggest that the use of such evaluations could have altered coverage decisions in a sizable proportion of drugs considered (research grant 2007-2008). More recently, together with Ariel Hammerman, one of my doctoral students, we proposed a framework for creating a financial risk-sharing mechanism between pharmaceutical and medical device companies, and the four Israeli health plans in adopting new technologies. The framework for this mechanism has been published a few years ago (refereed article #29), and two other manuscript presenting the results of the study examining the feasibility of our proposed mechanism have been published (refereed articles #47 and #57) While on sabbatical at Tufts Medical Center, we examined whether the United States is ready to use cost per QALY analyses (refereed article #32), and the potential to adopt decrementally cost-effective innovations in the health care market place (refereed article

#34). This concept has been examined in the doctoral dissertation of Ronen Arbel. One of the manuscripts has been recently published (refereed article # 65) and one is under review (submitted manuscript #2). Along with this concept we have recently addressed the economic consequences of using novel and expensive drugs to reduce LDL levels (submitted manuscript #5).

In addition to cost-effectiveness analysis, assessing actual patients' and potential patients' willingness to pay (through a contingent valuation study) may elicit patient preferences for healthcare. During my post-doctoral fellowship I conducted a study that assessed patients' willingness to pay for a technology that reduces the risk of re-narrowing of the coronary artery after a catheterization procedure. More recently we conducted in the United States a survey among a representative sample of the population to examine how the framing of survival benefit affects individuals' preferences for cancer therapies (refereed article # 52) Following this study, we conducted a survey among oncologists, primary care physicians, and the general public in Israel to assess the willingness to pay for improvements in survival, and quality of life, both for cancer interventions and other end-stage diseases. This study was supported by a research grant from the Israel National Institute for Health Policy and Health Services Research (Research grant 2011-2011). The first two manuscripts from this study have been published (refereed articles #51 and #54). We are also conducting a systematic review to examine the evidence on the willingness to pay for cancer-related treatments (manuscript in preparation #6).

Results from cost-effectiveness analyses are recently used for value-based insurance design, where co-payments for high-value drugs are reduced in order to increase patient adherence to drug therapy. We have recently summarized the up-to-date evidence on value-based co-payment in a review article (refereed article #34), and were the first to address low-value services in value-based insurance design (refereed article #39). Based on this experience we engaged in a study aiming to estimate the non-adherence problem among chronically-ill patients of Maccabi Healthcare Services, the impact of non-adherence on treatment outcomes and costs, and to examine the potential implications of introducing a value-based co-payment scheme (research grant 2011-2012). This study has already resulted in two peer-reviewed publications (refereed articles #58 and #61). A recently completed systematic review (refereed manuscript #64) has examined the evidence on the cost-effectiveness of adherence enhancing interventions for drugs and other interventions in healthcare.

Finally, in the last three years, I am part of a research group examining the socio-economic aspects of Crohn's disease. This effort has resulted in several publications (refereed articles #59, #60, #62 and #66) and submitted manuscript #3. Additional studies that have been presented at international conferences are expected to emerge into peer-reviewed manuscripts.